

Tables

Table 9: Age-specified contraceptive use rate in the five German National Health Surveys from 1984 to 1999

Age group (yrs)	T0			T1			T2			T3			BGS98		
	Total women	OC users	%	Total women	OC users	%	Total women	OC users	%	Total women (E, W)	OC users (E, W)	%(E, W)			
17-19										125 (51, 74)	64 (32, 32)	51.20 (62.7, 43.2)			
20-24										212 (67, 145)	128 (45, 83)	60.38 (67.2, 57.2)			
25-29	263	82	31.18	357	153	42.86	376	133	35.37	149	86	57.72	301 (85, 216)	109 (31, 78)	36.21 (36.5, 36.1)
30-34	253	58	22.92	315	91	28.89	365	85	23.28	163	90	55.21	383 (124, 259)	117 (53, 64)	30.55 (42.7, 24.7)
35-39	299	53	17.73	291	58	19.93	294	59	20.07	159	73	45.91	405 (141, 264)	116 (55, 61)	28.40 (39.0, 23.1)
40-44	315	42	13.33	252	30	11.90	282	32	11.35	131	32	24.43	348 (109, 239)	56 (29, 27)	16.09 (26.6, 11.3)
45-49	348	21	6.03	366	16	4.37	282	13	4.61	102	22	21.57	334 (113, 221)	28 (17, 11)	8.38 (15.0, 5.0)
50-54	235	2	0.85	312	5	1.60	360	6	1.67	148			273 (98, 175)	2 (2, 0)	0.73 (2.0, 0.0)
55-59	258			239			266			109			409 (149, 260)		
60-64	250			275			251			114			313 (113, 200)		
65-69	152			279			212			85			228 (88, 140)		
70-74													201 (79, 122)		
75-79													142 (49, 93)		
Total	2373	258	10.91	2686	353	13.14	2688	328	12.20	1160	303	26.12	3674 (1266, 2408)	620 (264, 356)	16.87 (20.85, 14.78)
25-54	1713	258	15.06	1893	353	18.65	1959	328	17.64	852	303	35.56	2044 (670, 1374)	428 (187, 241)	20.94 (27.91, 17.54)

Tables

Table 10: Age-specified HRT use rate in the five German National Health Surveys from 1984 to 1999

Age group (yrs)	T0			T1			T2			T3			BGS98	
	Total women	HRT users	%	Total women	HRT users	%	Total women	HRT users	%	Total women (E, W)	HRT users (E, W)	%(E, W)		
17-19										125 (51, 74)				
20-24										212 (67, 145)				
25-29	263			357			376			149			301 (85, 216)	
30-34	253			315	2	0.63	365	3	0.82	163			383 (124, 259)	4 (1, 3)
35-39	299			291	3	1.03	294	3	1.02	159	3	1.89	405 (141, 264)	4 (1, 3)
40-44	315	2	0.63	252	3	1.19	282	9	3.19	131	8	6.11	348 (109, 239)	15 (1, 14)
45-49	348	8	2.30	366	24	6.56	282	31	10.99	102	10	9.80	334 (113, 221)	60 (17, 43)
50-54	235	7	2.98	312	21	6.73	360	87	24.17	148	23	15.54	273 (98, 175)	90 (28, 62)
55-59	258	16	6.20	239	13	5.44	266	50	18.80	109	12	11.01	409 (149, 260)	143 (40, 103)
60-64	250	9	3.60	275	10	3.64	251	17	6.77	114	7	6.14	313 (113, 200)	67 (14, 53)
65-69	152	4	2.63	279	5	1.79	212	10	4.72	85			228 (88, 140)	29 (6, 23)
70-74										201 (79, 122)			10 (2, 8)	4.98 ((2.5, 6.6)
75-79										142 (49, 93)			5 (0, 5)	3.52 (0, 5.4)
Total	2373	46	1.94	2686	81	3.02	2688	210	7.81	1160	63	5.43	3674 (1266, 2408)	427 (110, 317)
40-69	1558	46	2.95	1723	76	4.41	1653	204	12.34	689	60	8.71	1905 (670, 1235)	404 (106, 298)
														21.23 (15.82, 24.13)

Tables

Table 11: Most frequently used oral contraceptive products (first ten) in the five German National Health Surveys from 1984 to 1999

	T0		T1		T2		T3		BGS98		Total	
	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)
1	Triquilar	25 (9.7)	Marvelon	57 (16.1)	Marvelon	83 (25.3)	Gravistat 125	82 (27.1)	Minisiston	76 (12.3)	Marvelon	199 (10.3)
2	Marvelon	23 (8.9)	Triquilar	50 (14.2)	Triquilar	34 (10.4)	Minisiston	61 (20.1)	Valette	59 (9.5)	Minisiston	137 (7.4)
3	Oviol	16 (6.2)	Oviol	30 (8.5)	Femovan	31 (9.4)	Trisiston	59 (19.5)	Trisiston	44 (7.1)	Triquilar	125 (6.7)
4	Trinordiol	13 (5.0)	Femovan	25 (7.1)	Oviol	24 (7.3)	Non Ovlon	38 (12.5)	Microgynon	39 (6.3)	Trisiston	103 (5.5)
5	Lyndiol	12 (4.6)	Trinordiol	16 (4.5)	Cilest	16 (4.9)	Ovosiston	30 (9.9)	Marvelon	36 (5.8)	Gravistat 125	100 (5.4)
6	Microgynon	12 (4.6)	Microgynon	14 (4.0)	Trinordiol	16 (4.9)	Sequostat	17 (5.6)	Diane 35	27 (4.3)	Oviol	80 (4.3)
7	Neogynon	12 (4.6)	Ovanon	14 (4.0)	Trinovum	12 (3.7)	Synphasec	3 (1.0)	Neo-Eunomin	27 (4.3)	Microgynon	69 (3.7)
8	Trinovum	12 (4.6)	Trinovum	10 (2.83)	Yermonil	11 (3.35)	Conceplan M	3 (1.0)	Trigoa	26 (4.19)	Femovan	62 (3.3)
9	Sequilar	10 (3.9)	Lyndiol	9 (2.5)	Tristep	10 (3.1)	Certostat	3 (1.0)	Lovelle	25 (4.0)	Valette	59 (3.2)
10	Tristep	10 (3.9)	Tristep	9 (2.5)	Minulet	9 (2.7)	Minulet	2 (0.7)	Femigoa	25 (4.0)	Trinordiol	55 (3.0)
Others		113 (43.8)	119 (33.7)		82 (25.0)		5 (1.7)		236 (38.1)		873 (46.9)	
Total		258 (100)	353 (100)		328 (100)		303 (100)		620 (100)		1862 (100)	

Tables

Table 13: Most frequently used HRT products (first ten) in the five German National Health Surveys from 1984 to 1999

	T0		T1		T2		T3		BGS98		Total	
	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)	Drugs	Freq. (%)
1	Presomen 1.25	13 (28,26)	Presomen 0.6 te	8 (9.88)	Presomen 0.6 Comp	41 (19.52)	Estraderm Tts Tts- 25	9 (14.29)	Kliogest N Klimonorm	35 (8.20)	Presomen 0.6 Comp	87 (10.5)
2	Ovestin	6 (13,04)	Cyclomenoret te	7 (8.64)	Estraderm Tts- 25	20 (9.52)	Klimonorm	9 (14.29)	Klimonorm	33 (7.73)	Estraderm Tts 50	48 (5.8)
3	Cycloprogyno va	3 (6,52)	Presomen 1.25	7 (8.64)	Cyclomenoret te	17 (8.10)	Presomen 0.6 Comp	9 (14.29)	Presomen 0.6 Comp	31 (7.26)	Presomen 0.6	48 (5.8)
4	Transannon Comp.	3 (6,52)	Presomen 0.6comp	6 (7.41)	Kliogest Tbl. Tts- 25	17 (8.10)	Estraderm Tts- 25	4 (6.35)	Cyclomenorette	22 (5.15)	Cyclomenorette	47 (5.7)
5	Oestrogynal Drg.	2 (4,35)	Presomen 1.25 Comp	6 (7.41)	Presomen 0.6	16 (7.62)	Presomen 0.6 Drg.	4 (6.35)	Estraderm Tts 50	22 (5.15)	Klimonorm	42 (5.1)
6	Presomen 1.25 Comp	2 (4,35)	Estraderm Tts 50	5 (6.17)	Estraderm Tts 50	12 (5.71)	Presomen 1.25 Comp	4 (6.35)	Kliogest Tbl.	20 (4.68)	Kliogest Tbl.	39 (4.7)
7	Presomen Spezial	2 (4,35)	Cycloprogyno va	4 (4.94)	Presomen 1.25	12 (5.71)	Chlormadinon	2 (3.17)	Presomen 0.6	19 (4.45)	Presomen 1.25	37 (4.5)
8	Synapause	2 (4,35)	Cyclooestrog ynal	4 (4.94)	Trisequens	11 (5.24)	Kliogest Tbl.	2 (3.17)	Sisare	17 (3.98)	Kliogest N	35 (4.2)
9	Cyclooestrog ynal	1 (2.17)	Ovestin	3 (3.70)	Presomen 1.25 Comp	10 (4.76)	Mestranol 0.05mg	2 (3.17)	Estracomb Tts	16 (3.75)	Estraderm Tts- 25	33 (4.0)
10	Estrifam	1 (2.17)	Presomen	3 (3.70)	Cycloprogyno va	6 (2.73)	Minisiston	2 (3.17)	Trisequens	15 (3.51)	Presomen 1.25 Comp	31 (3.7)
Others		11 (23.91)		28 (34.57)		48 (22.86)		16 (25.40)		194 (45.43)		380 (45.95)
Total		46 (100)		81 (100)		210 (100)		63 (100)		427 (100)		827 (100)

Tables

Table 14: Age distributions and proportions for contraceptive users and nonusers in the five National Health Surveys from 1984 to 1999 in Germany

Age group (yrs)	T0			T1			T2			T3			BGS98		
	Total women	OC users	Non-users	Total women	OC users	Non-users	Total women	OC users	Non-users	Total women	OC users	Non-users	Total women	OC users	Non-users
17-19													125 (5.3)	64 (10.3)	61 (3.5)
20-24													212 (8.9)	128 (20.6)	84 (4.8)
25-29	263 (15.4)	82 (31.8)	181 (12.4)	357 (18.9)	153 (43.3)	204 (13.2)	376 (19.2)	133 (40.5)	243 (14.9)	149 (21.2)	86 (28.4)	63 (15.7)	301 (12.6)	109 (17.6)	192 (10.9)
30-34	253 (14.8)	58 (22.5)	195 (13.4)	315 (16.6)	91 (25.8)	224 (14.5)	365 (18.6)	85 (25.9)	280 (17.2)	163 (23.2)	90 (29.7)	73 (18.2)	383 (16.1)	117 (18.9)	266 (15.1)
35-39	299 (17.5)	53 (20.5)	246 (16.9)	291 (15.4)	58 (16.4)	233 (15.1)	294 (15.0)	59 (18.0)	235 (14.4)	159 (22.6)	73 (24.1)	86 (21.4)	405 (17.0)	116 (18.7)	289 (16.4)
40-44	315 (18.4)	42 (16.3)	273 (18.8)	252 (13.3)	30 (8.5)	222 (14.4)	282 (14.4)	32 (9.8)	250 (15.3)	131 (18.6)	32 (10.6)	99 (24.7)	348 (14.6)	56 (9.0)	292 (16.6)
45-49	348 (20.3)	21 (8.14)	327 (22.5)	366 (19.3)	16 (4.5)	350 (22.7)	282 (14.4)	13 (4.0)	269 (16.5)	102 (14.5)	22 (7.3)	80 (20.0)	334 (14.0)	28 (4.5)	306 (17.4)
50-54	235 (13.7)	2 (0.8)	233 (16.0)	312 (16.5)	5 (1.4)	307 (19.9)	360 (18.0)	6 (1.8)	354 (21.7)				273 (11.5)	2 (0.3)	271 (15.4)
Mean*	39.3±8.9	33.3±6.5	40.5±8.8	39.3±9.0	32.3±6.6	40.9±8.6	39.3±8.9	33.0±6.6	40.5±8.8	36.1±6.9	33.9±6.1	37.7±7.0	34.3±8.7	29.8±8.0	36.1±8.3
Total	1713 (100)	258 (100)	1455 (100)	1893 (100)	353 (100)	1540 (100)	1959 (100)	328 (100)	1631 (100)	704 (100)	303 (100)	401 (100)	2381 (100)	620 (100)	1761 (100)
Chi-square	127.3, df=5, P=0.000			276.5, df=5, P=0.000			201.5, df=5, P=0.000			61.2, df=4, p=0.000			353.2, df=7, P=0.000		

*: t-test, comparison between contraceptive users and non users in the same survey, all p-values <.001; all mean values were weighted according to national population to represent population values.

Tables

Table 15: Age distributions and proportions for HRT users and nonusers in the five National Health Surveys from 1984 to 1999 in Germany

Age group (yrs)	T0			T1			T2			T3			BGS98		
	Total women	HRT users	Non-users	Total women	HRT users	Non-users	Total women	HRT users	Non-users	Total women	HRT users	Non-users	Total women	HRT users	Non-users
30-34				315 (13.5)	2 (2.5)	313 (13.9)	365 (15.8)	3 (1.4)	362 (17.2)				383 (12.6)	4 (0.9)	379 (14.5)
35-39				291 (12.5)	3 (3.7)	288 (12.8)	294 (12.7)	3 (1.4)	291 (13.8)	159 (20.8)	3 (4.8)	156 (22.3)	405 (13.3)	4 (0.9)	401 (15.4)
40-44	315 (20.2)	2 (4.3)	313 (20.7)	252 (10.8)	3 (3.7)	249 (11.1)	282 (12.2)	9 (4.3)	273 (13.0)	131 (17.2)	8 (12.7)	123 (17.6)	348 (11.5)	15 (3.5)	333 (12.8)
45-49	348 (22.3)	8 (17.4)	340 (22.5)	366 (15.7)	24 (29.6)	342 (15.2)	282 (12.2)	31 (14.8)	251 (11.9)	102 (13.4)	10 (15.9)	92 (13.1)	334 (11.0)	60 (14.1)	274 (10.5)
50-54	235 (15.1)	7 (15.2)	228 (15.1)	312 (13.4)	21 (25.9)	291 (12.9)	360 (15.6)	87 (41.4)	273 (13.0)	148 (19.4)	23 (36.5)	125 (17.9)	273 (9.0)	90 (21.1)	183 (7.0)
55-59	258 (16.6)	16 (34.8)	242 (16.0)	239 (10.3)	13 (16.0)	226 (10.1)	266 (11.5)	50 (23.8)	216 (10.3)	109 (14.3)	12 (19.9)	97 (13.9)	409 (13.5)	143 (33.5)	266 (10.2)
60-64	250 (16.0)	9 (19.6)	241 (15.9)	275 (11.8)	10 (12.3)	265 (11.8)	251 (10.9)	17 (8.1)	234 (11.1)	114 (14.9)	7 (11.1)	107 (15.3)	313 (10.3)	67 (15.7)	246 (9.4)
65-69	152 (9.8)	4 (8.7)	148 (9.8)	279 (12.0)	5 (6.2)	274 (12.2)	212 (9.2)	10 (4.8)	202 (9.6)				228 (7.5)	29 (6.8)	199 (7.6)
70-74													201 (6.6)	10 (2.3)	191 (7.3)
75-79													142 (4.7)	5 (1.2)	137 (5.3)
Mean*	54.1±8.3	56.5±6.5	54.0±8.4	49.1±11	51.8±7.9	49.0±11	49.0±11	52.9±6.9	48.6±12	48.6±8.8	51.8±6.5	48.4±9.0	51.1±13	56.5±8.2	50.3±14
Total	1558 (100)	46 (100)	1512 (100)	2329 (100)	81 (100)	2248 (100)	2312 (100)	210 (100)	2102 (100)	848 (100)	63 (100)	3036 (100)	427 (100)		
Chi-square	16.35, df=5, P=0.006			42.0, df=7, P=0.000			208.4, df=7, P=0.000			23.9, df=5, p=0.000			412.4, df=9, P=0.000		

*: t-test, comparison between HRT users and nonusers in the same survey, all p-values <.0001; all mean values were weighted according to national population to represent population values.

Tables

Table 16: Body weight and body mass index for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

	BMI classes/body weight	T0		T1		T2		T3		BGS98	
		Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	<10% Mean	85(32.9)	139(27.0)	109(30.9)	163(30.9)	95(29.0)	186(28.5)	77(25.4)	70(23.3)	182(29.4)	185(30.3)
	-10%~0	74(28.7)	150(29.1)	117(33.1)	150(28.4)	102(31.1)	181(27.7)	82(27.1)	53(17.7)	196(31.7)	165(27.0)
	0~+10%	51(19.8)	95(18.4)	64(18.1)	88(16.7)	59(18.0)	125(19.1)	64(21.1)	66(22.0)	110(17.8)	95(15.5)
	+10%~+20%	27(10.5)	52(10.1)	36(10.2)	56(10.6)	32(9.8)	62(9.5)	31(10.2)	42(14.0)	54(8.7)	65(10.6)
	+20%~+30%	10(3.9)	23(4.5)	10(2.8)	33(6.3)	23(7.0)	41(6.3)	23(7.6)	24(8.0)	30(4.9)	40(6.5)
	>+30%	11(4.3)	56(10.9)	17(4.8)	38(7.2)	17(5.2)	58(8.9)	26(8.6)	45(15.0)	46(7.4)	61(10.0)
	n (%)	258(100.0)	515(100.0)	353(100.0)	528(100.0)	328(100.0)	653(100.0)	303(100.0)	300(100.0)	618(100.0)	611(100.0)
Chi-square		11.10, df=5, p=.049		8.84, df=5, p=.115		5.14, df=5, p=.399		13.30, df=5, p=.020		8.30, df=5, p=.141	
Mean, kg/m ²		23.5±3.6^b		24.7±5.0		23.7±4.3		24.1±4.5		24.1±4.1	
Mean, kg		63.2±10.1^b		66.9±13.6		64.3±11.8		65.4±12.9		65.1±11.4^a	
HRT	<10% Mean	9(19.6)	25(11.0)	8(10.0)	50(12.3)	29(13.9)	51(8.1)	6(9.5)	19(7.5)	49(11.5)	54(6.4)
	-10%~0	12(26.1)	37(16.2)	18(22.5)	81(20.0)	49(23.6)	101(16.1)	12(19.0)	46(18.3)	84(19.8)	128(15.1)
	0~+10%	12(26.1)	55(24.1)	31(38.8)	97(24.0)	49(23.6)	136(21.7)	16(25.4)	40(15.9)	94(22.1)	161(18.9)
	+10%~+20%	6(13.0)	42(18.4)	14(17.5)	75(18.5)	39(18.8)	110(17.6)	12(19.0)	44(17.5)	88(20.7)	152(17.9)
	+20%~+30%	4(8.7)	27(11.8)	2(2.5)	48(11.9)	17(8.2)	85(13.6)	6(9.5)	40(15.9)	50(11.8)	132(15.5)
	>+30%	3(6.5)	42(18.4)	7(8.8)	54(13.3)	25(12.0)	143(22.8)	11(17.5)	63(25.0)	60(14.1)	223(26.2)
	n (%)	46(100.0)	228(100.0)	80(100.0)	405(100.0)	208(100.0)	626(100.0)	63(100.0)	252(100.0)	425(100.0)	850(100.0)
Chi-square		8.71, df=5, p=.122		12.92, df=5, p=.025		23.43, df=5, p=.000		5.52, df=5, p=.357		37.41, df=5, p=.000	
Mean, kg/m ²		25.0±3.9^a		26.9±4.7		25.7±4.0		26.4±4.8		25.9±4.3^a	
Mean, kg		66.1±9.3^a		69.4±13.0		67.0±10.4		69.0±13.2		68.8±11.5^b	

^a: p<0.05; ^b: p<0.001, t-test, comparison between users and controls in the same survey.

Tables

Table 17: Resident places of steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Resident place	T0		T1		T2		T3		BGS98		
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls	
Contraceptives	Countryside	34(13.2)	71(13.8)	69(19.5)	81(15.3)	45(13.7)	115(17.5)	108(35.6)	101(33.3)	141(22.7)	140(22.6)
	City (small)	70(27.1)	171(33.1)	102(28.9)	155(29.2)	90(27.4)	171(26.1)	53(17.5)	47(15.5)	157(25.3)	127(20.5)
	City (middle)	68(26.4)	120(23.3)	92(26.1)	140(26.4)	114(34.8)	166(25.3)	66(21.8)	76(25.1)	147(23.7)	172(27.7)
	City (large)	86(33.3)	154(29.8)	90(25.5)	154(29.1)	79(24.1)	204(31.1)	76(25.1)	79(26.1)	175(28.2)	181(29.2)
	n	258(100.0)	516(100.0)	353(100.0)	530(100.0)	328(100.0)	656(100.0)	303(100.0)	303(100.0)	620(100.0)	620(100.0)
	Chi-square	3.39, df=3, p=.335		3.26, df=3, p=.353		12.71, df=3, p=.005		1.36, df=3, p=.716		5.23, df=3, p=.156	
HRT	Countryside	7(15.2)	34(14.8)	9(11.1)	70(17.3)	24(11.4)	118(18.7)	17(27.0)	87(34.5)	71(16.6)	207(24.2)
	City (small)	8(17.4)	67(29.1)	22(27.2)	101(24.9)	38(18.1)	188(29.8)	12(19.0)	35(13.9)	77(18.0)	166(19.4)
	City (middle)	11(23.9)	58(25.2)	18(22.2)	103(25.4)	57(27.1)	149(23.7)	11(17.5)	67(26.6)	122(28.6)	216(25.3)
	City (large)	20(43.5)	71(30.9)	32(39.5)	131(32.3)	91(43.3)	175(27.8)	23(36.5)	63(25.0)	157(36.8)	265(31.0)
	n	46(100.0)	230(100.0)	81(100.0)	405(100.0)	210(100.0)	630(100.0)	63(100.0)	252(100.0)	427(100.0)	854(100.0)
	Chi-square	3.82, df=3, p=.281		3.03, df=3, p=.388		25.86, df=3, p=.000		5.91, df=3, p=.116		11.9, df=3, p=.008	

Countryside: residents under 5000; City (small): residents 5000-20000; City (middle): residents 20000-100000; City(large): residents over 100000.

Tables

Table 18: Marriage status for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

	Marriage status	T0		T1		T2		T3		BGS98	
		Users	Controls								
Contraceptives	Single	36(14.0)	77(14.9)	75(21.2)	104(19.6)	76(23.2)	175(26.7)	29(9.6)	32(10.6)	271(44.2)	242(39.9)
	Married	201(77.9)	410(79.5)	263(74.5)	402(75.8)	232(70.7)	449(68.4)	250(82.5)	245(80.9)	308(50.2)	328(54.1)
	Divorced	19(7.4)	22(4.3)	13(3.7)	21(4.0)	17(5.2)	24(3.7)	22(7.3)	22(7.3)	30(4.9)	34(5.6)
	Widowed	2(.8)	7(1.4)	2(.6)	3(.6)	3(.9)	8(1.2)	2(.7)	4(1.3)	4(.7)	2(.3)
	n	258(100.0)	516(100.0)	353(100.0)	530(100.0)	328(100.0)	656(100.0)	303(100.0)	303(100.0)	613(100.0)	606(100.0)
HRT	Chi-square	3.79, df=3, p=.286		.37, df=3, p=.946		2.62, df=3, p=.454		.87, df=3, p=.834		3.15, df=3, p=.370	
	Single	0(0)	17(7.4)	3(3.7)	32(7.9)	11(5.2)	40(6.3)	2(3.2)	17(6.7)	16(3.8)	36(4.4)
	Married	38(82.6)	173(75.2)	53(65.4)	298(73.6)	172(81.9)	466(74.0)	54(85.7)	179(71.0)	300(70.9)	599(72.5)
	Divorced	4(8.7)	9(3.9)	11(13.6)	28(6.9)	8(3.8)	40(6.3)	4(6.3)	26(10.3)	48(11.3)	63(7.6)
	Widowed	4(8.7)	31(13.5)	14(17.3)	47(11.6)	19(9.0)	84(13.3)	3(4.8)	30(11.9)	59(13.9)	128(15.5)
	n	46(100.0)	230(100.0)	81(100.0)	405(100.0)	210(100.0)	630(100.0)	63(100.0)	252(100.0)	423(100.0)	826(100.0)
	Chi-square	6.23, df=3, p=.101		7.75, df=3, p=.052		5.76, df=3, p=.124		5.82, df=3, p=.121		5.13, df=3, p=.163	

Tables

Table 19: Education for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

	Schools	T0		T1		T2		T3		BGS98	
		Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	Volks- Haupt	149(58.0)	285(55.4)	197(55.8)	260(49.1)	145(44.2)	271(41.3)	50(16.6)	62(20.5)	109(17.7)	138(22.8)
	Real-	65(25.3)	132(25.7)	96(27.2)	158(29.9)	110(33.5)	202(30.8)	196(65.1)	191(63.0)	284(46.2)	260(43.0)
	FH and Uni	41(16.0)	86(16.7)	50(14.2)	102(19.3)	66(20.1)	171(26.1)	53(17.6)	45(14.9)	200(32.5)	158(26.1)
	Others	2(.8)	11(2.1)	10(2.8)	9(1.7)	7(2.1)	12(1.8)	2(.7)	5(1.7)	22(3.6)	49(8.1)
	n	257(100.0)	514(100.0)	353(100.0)	529(100.0)	328(100.0)	656(100.0)	301(100.0)	303(100.0)	615(100.0)	605(100.0)
	Chi-square	2.15, df=3, p=.541		6.81, df=3, p=.078		4.27, df=3, p=.234		3.28, df=3, p=.350		19.58, df=3, p=.000	
HRT	Volks- Haupt	32(69.6)	178(77.4)	56(69.1)	300(74.1)	128(61.2)	467(74.1)	41(65.1)	159(63.6)	203(48.1)	467(56.6)
	Real-	9(19.6)	41(17.8)	16(19.8)	69(17.0)	57(27.3)	109(17.3)	12(19.0)	52(20.8)	133(31.5)	231(28.0)
	FH and Uni	4(8.7)	9(3.9)	6(7.4)	26(6.4)	21(10.0)	34(5.4)	10(15.9)	29(11.6)	71(16.8)	90(10.9)
	Others	1(2.2)	2(.9)	3(3.7)	10(2.5)	3(1.4)	20(3.2)	0(.0)	10(4.0)	15(3.6)	37(4.5)
	n	46(100.0)	230(100.0)	81(100.0)	405(100.0)	209(100.0)	630(100.0)	63(100.0)	250(100.0)	422(100.0)	825(100.0)
	Chi-square	2.83, df=3, p=.418		.994, df=3, p=.804		18.47, df=3, p=.000		3.35, df=3, p=.341		13.09, df=3, p=.004	

Tables

Table 20: Social classes for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Social class	T0		T1		T2		T3		BGS98	
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	Lower	48(18.8)	105(20.5)	60(17.0)	81(15.4)	45(13.7)	97(14.9)	38(12.5)	47(15.5)	107(17.5)
	Middle	156(60.9)	304(59.5)	234(66.5)	348(66.2)	200(61.0)	386(59.2)	216(71.3)	199(65.7)	397(64.8)
	Upper	52(20.3)	102(20.0)	58(16.5)	97(18.4)	83(25.3)	169(25.9)	49(16.2)	57(18.8)	109(17.8)
	n (%)	256(100.0)	511(100.0)	352(100.0)	526(100.0)	328(100.0)	652(100.0)	303(100.0)	303(100.0)	613(100.0)
	Chi-square	0.346, df=2, p=.841		0.820, df=2, p=.664		0.349, df=2, p=.840		2.25, df=2, p=.324		13.79, df=2, p=.001
	Average score	11.52±3.50	11.33±3.46	11.37±3.34	11.63±3.21	12.10±3.47	12.18±3.53	11.25±3.04	11.33±3.21	11.42±3.19^a
HRT	Lower	11(23.9)	88(38.6)	18(22.2)	131(32.5)	32(15.2)	207(33.0)	17(27.0)	83(33.1)	75(17.8)
	Middle	23(50.0)	117(51.3)	51(63.0)	209(51.9)	116(55.2)	325(51.8)	38(60.3)	138(55.0)	243(57.7)
	Upper	12(26.1)	23(10.1)	12(14.8)	63(15.6)	62(29.5)	96(15.3)	8(12.7)	30(12.0)	103(24.5)
	n (%)	46(100.0)	228(100.0)	81(100.0)	403(100.0)	210(100.0)	628(100.0)	63(100.0)	251(100.0)	421(100.0)
	Chi-square	10.0, df=2, p=.007		3.9, df=2, p=.143		34.6, df=2, p=.000		.864, df=2, p=.649		28.3, df=2, p=.000
	Average score	11.78±3.99 ^a	10.03±3.33	10.83±3.41	10.62±3.69	12.28±3.59 ^b	10.54±3.79	11.00±3.23 ^a	10.04±3.26	11.76±3.78 ^b

^a: p<0.05, ^b: p<0.001, t-test, comparison between users and controls in the same survey.

Tables

Table 21: Smoking status in steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Smoking status	T0		T1		T2		T3		BGS98		
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls	
Contraceptives	Current	111(43.2)	176(34.2)	153(43.3)	187(35.3)	128(39.0)	256(39.0)	86(28.4)	99(32.7)	252(41.0)	246(40.5)
	Former	57(22.2)	126(24.5)	68(19.3)	114(21.5)	76(23.2)	126(19.2)	60(19.8)	41(13.5)	80(13.0)	82(13.5)
	Never	89(34.6)	213(41.4)	132(37.4)	229(43.2)	124(37.8)	274(41.8)	157(51.8)	163(53.8)	283(46.0)	279(46.0)
	n (%)	257(100)	515(100)	353(100.0)	530(100.0)	328(100.0)	656(100.0)	303(100.0)	303(100.0)	615(100.0)	607(100.0)
	Chi-square	6.11, df=2, p=.047		5.85, df=2, p=.054		2.52, df=2, P=.283		4.60, df=2, p=.100		.073, df=2, p=.994	
HRT	Current	6(13.0)	48(20.9)	13(16.0)	91(22.5)	41(19.5)	140(22.2)	9(14.3)	38(15.1)	92(21.6)	166(20.1)
	Former	13(28.3)	22(9.6)	20(24.7)	58(14.3)	50(23.8)	92(14.6)	9(14.3)	27(10.7)	80(18.8)	120(14.5)
	Never	27(58.7)	160(69.6)	48(59.3)	256(63.2)	119(56.7)	398(63.2)	45(71.4)	187(74.2)	253(59.5)	540(65.4)
	n (%)	46(100.0)	230(100.0)	81(100.0)	405(100.0)	210(100.0)	630(100.0)	63(100.0)	252(100.0)	425(100.0)	826(100.0)
	Chi-square	12.43, df=2, p=.002		5.99, df=2, p=.050		9.51, df=2, p=.009		.637, df=2, p=.737		5.08, df=2, p=.079	

Tables

Table 22: Self-assessed health status for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

	Health status	T0		T1		T2		T3		BGS98	
		Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	Very good(1)	22(8.6)	43(8.3)	40(11.3)	62(11.7)	33(10.1)	71(10.8)	27(8.9)	27(8.9)	22(3.6)	22(3.6)
	Good(2)	129(50.4)	237(46.0)	173(49.0)	249(47.0)	171(52.1)	313(47.8)	159(52.5)	145(47.9)	168(27.3)	147(24.2)
	Satisfied(3)	85(33.2)	178(34.6)	119(33.7)	181(34.2)	92(28.0)	192(29.3)	94(31.0)	108(35.6)	390(63.4)	385(63.4)
	Bad(4)	20(7.8)	57(11.1)	21(5.9)	38(7.1)	32(9.7)	79(12.1)	23(7.6)	23(7.6)	35(5.7)	53(8.8)
	Average score	2.41±0.79	2.50±0.84	2.35±0.78	2.38±0.82	2.38±0.81	2.44±0.86	2.38±0.78	2.43±0.79	2.72±0.64	2.78±0.67
	n	256(100.0)	515(100.0)	353(100.0)	530(100.0)	328(100.0)	655(100.0)	303(100.0)	303(100.0)	615(100.0)	607(100.0)
HRT	Chi-square	2.61, df=3, p=.456		.692, df=3, p=.875		2.11, df=3, p=.549		1.62, df=3, p=.656		5.06, df=3, p=.167	
	Good(2)**	12(26.1)	63(27.4)	29(35.8)	149(36.8)	76(36.2)	226(35.9)	10(15.9)	82(32.5)	32(7.5)	81(9.8)
	Satisfied(3)	23(50.0)	109(47.4)	36(44.4)	188(46.4)	95(45.2)	283(44.9)	36(57.1)	114(45.2)	280(65.9)	538(64.9)
	Bad(4)	11(23.9)	58(25.2)	16(19.8)	68(16.8)	39(18.6)	121(19.2)	17(27.0)	56(22.2)	113(26.6)	210(25.3)
	Average score	3.04±0.84	3.01±0.85	2.83±0.80	2.80±0.86	2.83±0.81	2.81±0.84	3.14±0.90^a	2.88±0.87	3.21±0.66	3.17±0.69
	n	46(100.0)	230(100.0)	81(100.0)	405(100.0)	210(100.0)	630(100.0)	63(100.0)	252(100.0)	425(100.0)	829(100.0)
	Chi-square	.105, df=2, p=.949		.418, df=2, p=.811		.041, df=2, p=.980		6.79, df=2, p=.034		1.78, df=2, p=.411	

*: Based on 4 scales: 1 very good; 2 good; 3 satisfied; 4 bad; **: covering 'very good' because of very low frequencies in this group.

^a: p<0.05, t-test, comparison between users and controls in the same survey.

Tables

Table 23: Satisfaction with life for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

	Satisfactory with your...?*	T0		T1		T2		T3		BGS98	
		Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	Job	5.57±1.31	5.49±1.34	5.51±1.36	5.42±1.40	5.36±1.38	5.27±1.47	4.69±1.85	4.60±1.92	5.09±1.58	4.90±1.72
	Residence	5.93±1.43	5.84±1.43	5.87±1.43	5.83±1.43	5.81±1.43	5.66±1.64	5.34±1.67	5.37±1.71	5.74±1.37	5.62±1.44
	Financial situ.	5.02±1.55	5.04±1.64	5.26±1.5	5.26±1.54	5.17±1.58	5.15±1.56	4.39±1.56	4.40±1.58	4.63±1.59	4.48±1.66
	Recreation	5.24±1.53	5.16±1.52	5.46±1.45	5.36±1.4	5.18±1.59	5.14±1.55	4.83±1.54	4.69±1.56	5.04±1.43	5.10±1.47
	Health	5.43±1.43	5.27±1.5	5.60±1.29	5.49±1.27	5.38±1.46	5.23±1.52	5.30±1.41^a	5.03±1.51	5.46±1.25	5.33±1.42
	Family situ.	5.76±1.47	5.84±1.44	6.04±1.3	6.02±1.34	5.91±1.54	5.79±1.60	6.08±1.35	5.95±1.33	5.79±1.40	5.79±1.43
	Relations to frnds, neibr,..	6.04±1.08	5.99±1.12	6.05±1.1	6.10±0.95	5.97±1.17	5.96±1.18	6.02±1.1	5.96±1.15	5.99±1.09	5.94±1.17
	Life (totally)	5.65±1.15	5.65±1.12	5.83±1.08	5.78±1.03	5.74±1.2	5.66±1.17	5.43±1.18	5.51±1.11	5.57±1.07	5.48±1.25
HRT	Job	5.67±1.38	5.87±1.23	5.78±1.16	5.66±1.37	5.46±1.5	5.52±1.4	4.76±1.87	4.61±1.96	5.14±1.62^a	5.37±1.54
	Residence	6.25±1.4	6.35±1.20	6.27±1.11	6.35±1.15	6.13±1.43	6.19±1.32	6.14±1.16^a	5.53±1.66	6.11±1.19	6.11±1.21
	Financial situ.	5.57±1.37	5.68±1.52	5.42±1.64	5.76±1.55	5.74±1.47	5.54±1.55	4.90±1.46^a	4.43±1.70	5.21±1.64	5.21±1.59
	Recreation	5.59±1.65	5.84±1.50	5.83±1.43	5.67±1.48	5.72±1.43	5.53±1.55	5.44±1.68	5.27±1.55	5.34±1.59	5.46±1.5
	Health	4.64±1.87	4.72±1.84	5.00±1.42	5.08±1.61	4.70±1.63	4.82±1.68	4.41±1.8	4.79±1.68	4.74±1.6^a	5.01±1.56
	Family situ.	5.95±1.31	5.94±1.31	5.68±1.56	6.00±1.37	5.98±1.45	5.85±1.5	6.10±1.24	5.87±1.43	5.66±1.5	5.80±1.37
	Relations to frnds, neibr,..	5.82±1.37	6.10±1.18	6.07±1.15	6.22±1.01	6.02±1.16	6.07±1.22	6.19±1.01	6.12±1.01	5.99±1.15	5.94±1.18
	Life (totally)	5.77±1.18	5.86±1.22	5.85±1.07	5.89±1.11	5.79±1.29	5.75±1.29	5.40±1.25	5.34±1.25	5.57±1.25	5.66±1.21

*: Based on 7 scores from 1 (very unsatisfactory) to 7 (very satisfactory) for every item.

^a: p<=0.05, t-test, comparison between users and controls in the same survey.

Tables

Table 24: SF-36 scores for steroid hormone users and controls in the survey BGS98

		Physical functioning	Role physical ¹	Body pain	General health	Vitality energy	Social function	Role emotional ²	Mental health	Change in health
Contraceptive	Users	93.65±11.4	92.77±20.8	70.53±23.1	73.38±15.3	58.64±16.4	87.46±17.9	90.89±21.7	71.63±15.3	2.89±0.68
	Controls	91.84±14.3	84.89±29.4	68.98±25.1	71.21±16.3	57.33±17.3	85.77±19.8	89.05±25.8	70.17±16.6	2.85±0.75
	p value	.015	.000	.262	.017	.176	.117	.181	.109	.314
HRT	Users	78.13±22.2	72.90±38.1	56.42±25.7	61.78±19.0	56.41±18.9	83.62±21.2	84.54±31.5	68.42±18.3	3.08±0.73
	Controls	77.97±23.6	76.72±35.6	61.74±26.3	62.69±18.8	58.84±18.5	84.44±21.5	86.52±30.6	69.66±18.0	2.98±0.72
	p value	.913	.087	.001	.426	.030	.520	.286	.252	.013

¹ : role limitation due to physical problems; ²: role limitation due to emotional problems

Tables

Table 25: History of diseases/symptoms for contraceptive users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Diseases/symptoms	T0			T1			T2			T3			BGS98		
	Users	Contr.	p*	Users	Contr.	p*	Users	Contr.	p*	Users	Contr.	p*	Users	Contr.	p*
Ischemia myocardial	3.1%	3.9%	.586	1.4%	1.5%	.918	1.2%	2.0%	.393	2.0%	2.6%	.584	.5%	1.3%	.124
Myocardiac infarction	.0%	.0%	-	.0%	.0%	-	0%	.2%	1.00	0%	0.3%	1.00	.0%	.0%	-
Cardiac insufficiency	.8%	1.2%	.900	.3%	1.5%	.152	1.2%	.8%	.726	2.0%	1.7%	.761	.2%	.8%	.214
Cerebral circulation dis.	2.3%	3.1%	.541	1.4%	1.3%	1.00	2.1%	2.5%	.763	.3%	1.0%	.616	.8%	1.0%	.745
Stroke	0%	.6%	.555	0%	.2%	1.00	.6%	0%	.111	0%	0%	-	.0%	.3%	.247
Varicosity, thrombosis	18.2%	25.4%	.025	19.0%	21.3%	.409	13.8%	19.0%	.042	12.5%	16.2%	.203	12.0%	10.7%	.472
Arterial occlusion in legs	8.1%	10.9%	.235	6.3%	9.1%	.136	8.0%	9.6%	.406	2.3%	5.5%	.040	2.0%	1.3%	.385
Arthritis	9.7%	11.4%	.462	8.3%	7.9%	.847	9.5%	9.7%	.921	5.0%	8.6%	.075	4.1%	3.3%	.475
Gout and lithemia	0%	2.5%	.006	1.1%	2.1%	.288	1.5%	2.1%	.510	.0%	1.0%	.249	1.0%	1.0%	.982
Diabetes	0%	2.1%	.041	.9%	.9%	1.00	.9%	1.4%	.756	0%	2.0%	.040	.5%	1.5%	.078
Asthma	3.9%	1.9%	.109	2.0%	2.8%	.435	4.3%	3.2%	.394	Data unavailable			7.3%	7.1%	.875
Chronic bronchitis	5.4%	4.8%	.727	4.8%	5.5%	.674	8.6%	6.7%	.302	Data unavailable			5.9%	6.1%	.853
Hepatitis , fatty liver	1.9%	5.6%	.018	2.6%	4.5%	.130	2.5%	3.2%	.508	4.6%	7.0%	.219	2.0%	3.6%	.076
Cholecystitis, gallstone	5.4%	7.4%	.310	4.8%	5.7%	.591	4.9%	4.4%	.742	8.6%	7.6%	.655	5.2%	2.8%	.032
Gastric, duodenal ulcer	4.7%	5.4%	.646	7.6%	2.3%	.000	5.8%	5.7%	.922	1.7%	4.3%	.056	2.4%	2.5%	.964
Gastritis	16.7%	19.4%	.359	22.1%	21.7%	.893	24.5%	21.6%	.310	8.6%	8.6%	1.00	18.9%	17.8%	.639
Thyropathy	20.9%	19.6%	.657	15.6%	22.5%	.012	16.6%	20.4%	.148	13.2%	14.9%	.559	16.8%	18.8%	.352
Urinary diseases	25.2%	31.6%	.066	26.6%	21.9%	.109	21.9%	22.3%	.894	12.3%	14.6%	.412	15.3%	14.5%	.699
Constipation	14.0%	19.6%	.053	20.5%	23.2%	.330	18.3%	22.8%	.111	9.3&	9.6%	.900	Data unavailable		
Hay fever	8.5%	7.9%	.780	10.0%	12.6%	.236	17.9%	12.3%	.018	7.0%	6.3%	.743	20.4%	19.5%	.698
Other allergy	27.1%	29.5%	.500	28.4%	28.4%	.993	27.8%	30.0%	.476	19.5%	17.2%	.462	21.2%	19.7%	.513
Cancers	.4%	1.2%	.502	0%	1.2%	.110	1.2%	1.1%	1.00	1.3%	3.3%	.106	1.0%	1.6%	.302
Lumbago, sciatica	12.8%	16.9%	.140	15.7%	14.7%	.699	16.8%	19.7%	.273	9.6%	11.2%	.506	7.3%	9.1%	.262

*: Chi-square test, continuity corrected Chi-square test or Fisher's exact test, when necessary

Tables

Table 26: History of diseases/symptoms for HRT users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Diseases/symptom	T0			T1			T2			T3			BGS98		
	Users	Contr.	p*	Users	Contr.	p*	Users	Contr.	p*	Users	Contr.	p*	Users	Contr.	p*
Ischemia myocardial	10.9%	15.7%	.405	13.6%	10.4%	.398	9.6%	13.7%	.120	19.0%	11.5%	.112	6.1%	8.1%	.211
Myocardiac infarction	2.2%	3.9%	.885	.0%	.0%	-	.5%	1.8%	.311	.0%	.4%	1.00	.7%	1.9%	.093
Cardiac insufficiency	8.7%	9.6%	.854	10.0%	9.5%	.879	7.7%	10.7%	.207	9.7%	6.7%	.602	5.4%	5.7%	.847
Cerebral circulation dis.	17.4%	10.9%	.213	12.3%	9.1%	.372	11.5%	8.3%	.165	4.8%	5.2%	.898	2.6%	1.4%	.153
Stroke	.0%	1.7%	1.00	.0%	1.2%	.596	.5%	1.0%	.828	.0%	.0%	-	1.4%	1.1%	.614
Varicosity, thrombosis	43.5%	47.4%	.627	38.8%	34.8%	.501	34.8%	40.4%	.151	22.2%	21.9%	.958	36.8%	39.9%	.294
Arterial occlusion in legs	10.9%	21.3%	.103	16.3%	20.1%	.421	21.1%	23.1%	.553	7.9%	14.8%	.153	8.3%	10.0%	.327
Arthritis	37.0%	43.0%	.445	35.8%	26.6%	.091	42.2%	29.7%	.001	25.4%	17.5%	.151	54.9%	44.9%	.001
Gout and lithemia	6.5%	9.1%	.774	14.8%	8.6%	.086	7.7%	9.1%	.520	3.2%	1.6%	.757	5.9%	7.5%	.287
Diabetes	6.5%	7.0%	.915	4.9%	4.2%	1.00	3.8%	5.7%	.279	6.3%	4.0%	.632	4.3%	6.7%	.087
Asthma	2.2%	3.9%	.885	4.9%	2.2%	.317	5.7%	4.5%	.449	Data unavailable			8.5%	6.6%	.229
Chronic bronchitis	4.3%	8.3%	.542	7.4%	5.9%	.805	10.0%	8.4%	.583	Data unavailable			10.9%	8.2%	.122
Hepatitis , fatty liver	21.7%	14.3%	.207	2.5%	7.2%	.115	10.0%	9.1%	.685	7.9%	8.4%	.912	7.6%	7.2%	.838
Cholecystitis, gallstone	17.4%	21.3%	.550	9.9%	16.8%	.118	20.0%	18.9%	.730	22.2%	19.0%	.571	19.1%	22.7%	.142
Gastric, duodenal ulcer	6.5%	11.3%	.483	12.3%	12.8%	.921	10.5%	10.4%	.959	3.2%	7.9%	.185	9.2%	9.4%	.923
Gastritis	23.9%	20.0%	.550	25.9%	25.1%	.870	32.9%	25.5%	.038	17.5%	14.7%	.583	34.5%	26.7%	.004
Thyropathy	26.1%	22.2%	.564	22.2%	24.9%	.604	26.2%	22.2%	.241	19.0%	18.7%	.942	27.4%	24.7%	.296
Urinary diseases	32.6%	37.8%	.503	18.5%	24.6%	.243	28.7%	19.2%	.004	31.7%	15.1%	.002	26.5%	20.8%	.022
Constipation	37.0%	29.6%	.322	33.3%	29.4%	.476	29.2%	24.9%	.223	23.8%	24.8%	.870	Data unavailable		
Hay fever	4.3%	5.2%	1.00	6.2%	4.5%	.710	10.5%	7.5%	.172	3.2%	6.4%	.329	18.2%	12.9%	.013
Other allergy	21.7%	21.7%	1.00	22.2%	21.3%	.846	27.9%	19.9%	.016	15.9%	19.8%	.473	20.7%	13.0%	.000
Cancers	2.2%	8.3%	.253	2.5%	3.3%	.991	1.9%	4.3%	.114	7.9%	4.0%	.186	5.7%	7.3%	.291
Lumbago, sciatica	32.6%	29.1%	.637	32.5%	33.9%	.807	39.1%	31.6%	.046	22.2%	22.6%	.946	47.8%	38.6%	.002

*: Chi-square test, continuity corrected Chi-square test or Fisher's exact test, when necessary

Tables

Table 27: Diseases histories for hormone users and controls from survey BGS98 only

		Hypoferic anemia	Osteoporo sis	Migraine	Epilepsy	Parkinson disease	Meningitis	Mental disorders	Addictive disorders	Neuro- dermatitis	Disorders. in uterus, ovary
Contraceptive	Users	22.9%	.3%	23.8%	.0%	.0%	.8%	8.1%	.7%	9.6%	9.9%
	Controls	29.2%	.5%	26.1%	1.2%	.2%	2.3%	13.2%	2.0%	6.8%	12.0%
	p value*	.012	.642	.354	.007	.496	.035	.004	.041	.069	.245
HRT	Users	22.7%	13.6%	30.9%	1.2%	.5%	.2%	22.2%	2.6%	5.7%	36.5%
	Controls	18.5%	8.8%	23.8%	.5%	.6%	1.3%	15.4%	1.2%	4.8%	27.0%
	p value*	.081	.009	.007	.176	1.00	.117	.003	.070	.522	.001

*: Chi-square test, continuity corrected Chi-square test or Fisher's exact test, when necessary, comparing between users and controls.

Tables

Table 28: Prevalence of unspecific diseases /symptoms among contraceptive users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Diseases/symptom	T0			T1			T2			T3			BGS98		
	Users	Contr	p*	Users	Contr	p*	Users	Contr	p*	Users	Contr	p*	Users	Contr	p*
Lump Feeling in the throat	8.9%	14.0%	.044	11.3%	11.7%	.915	11.3%	12.2%	.714	6.6%	9.6%	.180	8.8%	7.9%	.593
Shortness of breath	15.6%	13.9%	.517	13.9%	14.9%	.697	12.6%	13.4%	.764	7.9%	9.2%	.562	9.6%	10.6%	.561
Feeling of weakness	16.7%	17.5%	.787	15.6%	15.7%	.975	13.5%	17.7%	.098	9.9%	13.5%	.165	12.4%	17.0%	.021
Swallowing difficulty	6.6%	6.0%	.742	3.4%	3.6%	.875	6.8%	5.8%	.556	3.7%	3.0%	.633	3.9%	6.8%	.027
Stitch, torsion spasm or pain in chest	15.6%	13.8%	.507	12.5%	15.1%	.271	13.4%	13.6%	.947	11.2%	15.5%	.121	7.5%	8.8%	.413
Feeling of pressure or fullness in abdomen	19.8%	19.0%	.787	14.4%	16.8%	.350	20.1%	17.7%	.359	19.1%	17.8%	.675	19.2%	16.2%	.172
Languor, fatigue	37.0%	37.1%	.974	30.0%	33.6%	.268	33.5%	36.2%	.413	24.4%	31.0%	.070	27.0%	27.4%	.884
Nausea	9.3%	9.0%	.878	5.4%	10.4%	.009	7.0%	7.3%	.857	7.7%	8.3%	.800	6.8%	8.1%	.403
Heartburn, acid eructation	14.0%	11.7%	.360	9.6%	11.3%	.425	9.5%	11.9%	.257	7.6%	9.6%	.384	10.6%	12.1%	.403
Irritability, oversensitive	45.1%	38.6%	.082	44.7%	41.9%	.404	43.0%	40.8%	.505	27.1%	36.3%	.014	35.9%	33.3%	.350
Blues	37.0%	33.1%	.292	33.4%	33.0%	.899	35.7%	37.2%	.640	26.4%	29.4%	.415	38.9%	36.5%	.380
Sudoresis	27.2%	24.5%	.404	29.7%	24.2%	.070	25.4%	23.2%	.451	23.8%	25.4%	.637	17.1%	18.9%	.397
Lumbago and backache	53.1%	53.8%	.862	53.0%	54.3%	.690	50.5%	58.1%	.023	50.8%	52.5%	.684	44.6%	47.2%	.370
Subjective feeling of unrest	42.8%	38.5%	.253	40.2%	37.7%	.457	42.4%	42.7%	.912	26.4%	28.7%	.525	34.7%	34.2%	.342
Feeling of heaviness and weakness in legs	31.9%	31.8%	.986	22.4%	24.7%	.424	26.5%	26.7%	.713	17.8%	24.4%	.047	16.6%	19.6%	.166
Tension in legs	18.5%	16.3%	.454	11.6%	12.8%	.601	15.3%	15.3%	.992	9.6%	11.9%	.351	7.8%	9.9%	.200
Hypersensitive to heat	14.8%	18.1%	.254	16.8%	16.6%	.951	15.1%	14.7%	.876	15.2%	23.8%	.007	10.9%	11.7%	.657
Hypersensitive to cold	32.3%	29.5%	.429	28.3%	27.9%	.896	28.7%	28.7%	1.00	28.7%	31.0%	.534	23.9%	23.8%	.954
Sleeping insufficiency	32.4%	32.0%	.915	24.6%	24.9%	.930	30.3%	33.3%	.342	34.7%	34.7%	1.00	33.9%	29.7%	.121
Insomnia	15.6%	15.1%	.862	11.3%	11.1%	.927	13.5%	13.9%	.844	12.9%	15.9%	.289	13.5%	13.2%	.871
Dizziness, vertigo	22.2%	21.6%	.843	21.8%	24.5%	.351	23.2%	23.0%	.938	13.9%	18.2%	.150	14.8%	17.3%	.238
Tremble	10.9%	8.7%	.334	9.1%	9.6%	.781	8.5%	7.8%	.678	5.0%	10.6%	.010	4.9%	7.6%	.051
Pain in neck and scapula	44.0%	41.7%	.556	41.9%	42.8%	.790	45.4%	46.0%	.856	38.7%	44.7%	.137	37.2%	34.9%	.391
Loss of weight	6.2%	6.2%	.995	4.0%	5.5%	.309	8.6%	7.6%	.607	4.6%	6.6%	.285	4.9%	7.3%	.080

*: Chi-square test, continuity corrected Chi-square test or Fisher's exact test, when necessary

Tables

Table 29: Prevalence of unspecific diseases/symptoms among HRT users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Diseases/symptom	T0			T1			T2			T3			BGS98		
	Users	Contr	p*												
Lump Feeling in the throat	13.0%	13.1%	.992	19.8%	16.8%	.526	18.2%	17.4%	.786	17.5%	12.0%	.246	14.4%	14.5%	.927
Shortness of breath	26.7%	21.1%	.406	21.0%	20.5%	.928	28.2%	23.5%	.168	19.0%	17.9%	.837	20.9%	20.4%	.827
Feeling of weakness	28.3%	27.5%	.917	21.0%	22.0%	.836	25.2%	20.8%	.179	20.6%	17.9%	.621	21.7%	18.6%	.187
Swallowing difficulty	4.3%	5.2%	.802	9.9%	5.7%	.162	10.5%	6.6%	.065	9.5%	6.4%	.386	7.1%	6.5%	.723
Stitch, torsion spasm or pain in chest	21.7%	23.6%	.787	25.9%	19.4%	.181	25.8%	22.9%	.384	30.2%	16.3%	.013	13.0%	12.5%	.800
Feeling of pressure or fullness in abdomen	21.7%	27.1%	.453	38.3%	27.7%	.057	31.0%	28.9%	.566	34.9%	28.3%	.302	31.4%	27.4%	.144
Languor, fatigue	52.2%	35.8%	.037	36.3%	35.6%	.906	40.0%	37.8%	.566	38.1%	32.7%	.415	39.6%	31.2%	.003
Nausea	17.4%	11.4%	.261	12.3%	10.4%	.600	8.3%	9.7%	.528	15.9%	12.0%	.404	9.4%	7.6%	.271
Heartburn, acid eructation	26.1%	19.2%	.291	17.5%	22.0%	.371	22.5%	24.7%	.521	17.5%	21.5%	.478	22.6%	22.2%	.883
Irritability, oversensitive	47.8%	36.7%	.156	43.2%	39.0%	.481	42.6%	37.4%	.184	41.3%	37.2%	.552	36.0%	31.3%	.095
Blues	42.2%	37.6%	.556	48.1%	39.5%	.149	41.4%	37.9%	.363	42.9%	37.8%	.466	41.8%	36.4%	.063
Sudoresis	50.0%	41.9%	.313	42.0%	41.1%	.882	47.4%	45.4%	.620	39.7%	41.0%	.845	36.0%	37.7%	.556
Lumbago and backache	71.7%	63.3%	.275	58.8%	64.7%	.313	67.0%	67.0%	1.00	79.4%	59.6%	.004	71.3%	59.1%	.000
Subjective feeling of unrest	50.0%	49.3%	.935	51.9%	47.2%	.440	52.4%	49.6%	.486	60.3%	43.4%	.016	44.0%	41.0%	.312
Feeling of heaviness and weakness in legs	45.7%	52.0%	.434	38.3%	45.4%	.236	44.3%	48.2%	.319	36.5%	40.2%	.588	39.1%	39.9%	.779
Tension in legs	34.8%	33.6%	.880	25.9%	26.7%	.881	31.4%	30.4%	.776	23.8%	28.7%	.439	24.8%	23.5%	.618
Hypersensitive to heat	37.0%	31.9%	.503	19.8%	31.6%	.033	29.7%	32.8%	.400	34.9%	36.7%	.798	20.0%	23.9%	.125
Hypersensitive to cold	37.0%	37.6%	.939	32.1%	29.6%	.658	40.0%	35.1%	.199	30.2%	34.3%	.537	35.1%	30.8%	.119
Sleeping insufficiency	30.4%	28.8%	.826	30.9%	23.5%	.158	33.3%	27.7%	.110	30.2%	24.8%	.385	32.7%	27.8%	.070
Insomnia	47.8%	39.5%	.293	33.3%	32.4%	.874	37.8%	36.4%	.709	42.9%	35.1%	.251	38.4%	36.4%	.497
Dizziness, vertigo	50.0%	32.3%	.022	21.0%	27.0%	.262	23.8%	25.4%	.637	30.2%	18.7%	.046	20.9%	19.5%	.544
Tremble	10.9%	13.1%	.679	13.6%	10.4%	.398	9.5%	11.3%	.477	15.9%	12.4%	.458	7.6%	6.2%	.336
Pain in neck and scapula	76.1%	59.4%	.033	59.3%	56.7%	.669	69.0%	57.9%	.004	69.4%	56.8%	.072	65.9%	55.6%	.000
Loss of weight	8.7%	6.2%	.529	2.5%	5.9%	.206	6.2%	6.2%	1.00	6.3%	9.2%	.476	3.8%	5.4%	.193

*: Chi-square test, continuity corrected Chi-square test or Fisher's exact test, when necessary

Tables

Table 30: Menstrual cycles for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

		T0		T1		T2		T3		BGS98		
		Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls	
Contraceptives	Have you cycles ?	Yes ¹	251(97.7%)	424(82.8%)	347(99.1)	459(88.8)	325(99.4%)	576(88.9%)	302(99.7%)	273(90.1%)	616(99.5%)	580(94.3%)
		No	6(2.3%)	88(17.2%)	3(.9%)	58(11.2%)	2(.6%)	72(11.1%)	1(.3%)	30(9.9%)	3(.5%)	35(5.7%)
		χ^2	35.18, p=.000		34.26, p=.000		34.16, p=.000		28.59, p=.000		28.0, p=.000	
	Are cycles regular?	Yes ¹	251(100%)	424(100%)	343(98.8%)	440(95.9%)	316(97.2%)	546(94.8%)	300(99.3%)	271(99.3%)	601(97.6%)	500(86.1%)
		No	0	0	4(1.2%)	19(4.1%)	9(2.8%)	30(5.2%)	2(.7%)	2(.7%)	15(2.4%)	80(13.9%)
		χ^2	-		6.36, p=.012		2.99, p=.084		.000, p=1.00		53.7, p=.000	
HRT	² Age at menarche	Data unavailable		Data unavailable		Data unavailable		Data unavailable		13.33±1.60^a	13.09±1.05	
	Have you cycles ?	Yes ¹	5(10.9%)	36(15.8%)	20(24.7%)	116(29.3%)	52(24.9%)	143(23.0%)	18(29.0%)	89(35.3%)	133(32.0%)	176(21.4%)
		No	41(89.1%)	192(84.2%)	61(75.3%)	280(75.7%)	157(75.1%)	479(77.0%)	44(71.0%)	163(64.7%)	283(68.0%)	645(78.6%)
		χ^2	0.728, p=.393		0.699, p=.403		0.311, p=.577		0.875, p=.370		16.35, p=.000	
	Are cycles regular?	Yes ¹	5(100%)	36(100%)	16(80.0%)	105(90.5%)	49(94.2%)	134(93.7%)	18(100%)	88(98.9%)	109(82.6%)	136(77.3%)
		No	0	0	4(20.0%)	11(9.5%)	3(5.8%)	9(6.3%)	0	1(1.1%)	23(17.4%)	40(22.7%)
^{2,3} Age at menopause	² Age at menarche	Data unavailable		Data unavailable		Data unavailable		Data unavailable		13.70±1.73	13.64±1.70	
	^{2,3} Age at menopause	Data unavailable		Data unavailable		Data unavailable		Data unavailable		46.30±6.90^a	47.45±6.99	

¹: including those women who are pregnant. ²: weighted according to German national population 1998, ³: only among postmenopausal women.

^a: p<0.05, t-test, comparison between users and controls in the same survey.

Tables

Table 31: Number of pregnancies and age at first term pregnancy for steroid hormone users and controls in the four National Health Surveys from 1984 to 1991 in Germany

	Number of term pregnancies	T0		T1		T2		T3	
		Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	0	66(25.6)	143(27.7)	103(29.3)	152(28.9)	103(31.8)	224(34.8)	15(5.0)	36(11.9)
	1	75(29.1)	136(26.4)	97(27.6)	133(25.3)	92(28.4)	169(26.2)	93(30.7)	86(28.4)
	2	93(36.0)	164(31.8)	117(33.2)	179(34.0)	108(33.3)	170(26.4)	165(54.5)	134(44.2)
	≥3	24(9.3)	73(14.1)	35(9.9)	62(11.8)	21(6.5)	81(12.6)	30(9.9)	47(15.5)
	n (%)	258(100.0)	516(100.0)	352(100.0)	526(100.0)	324(100.0)	644(100.0)	303(100.0)	303(100.0)
	Chi-square	4.92, df=3, p=.178		1.11, df=3, p=.774		12.16, df=3, p=.007		15.89, df=3, p=.001	
	Pregnancies(mean) [*]	1.27±1.01	1.31±1.15	1.23±1.03	1.31±1.07	1.17±0.95	1.20±1.14	1.67±0.75	1.66±1.00
HRT	Age at 1 st pregnancy [*]	23.90±4.59	23.69±4.03	23.93±3.84	23.85±4.03	23.66±3.81	24.18±4.07	22.05±2.74	22.09±3.19
	0	6(13.0)	31(13.5)	10(12.3)	63(15.7)	33(15.8)	77(12.3)	6(9.5)	18(7.1)
	1	18(39.1)	49(21.3)	23(28.4)	98(24.4)	52(24.9)	147(23.5)	8(12.7)	74(29.4)
	2	15(32.6)	82(35.7)	26(32.1)	122(30.3)	72(34.4)	205(32.7)	36(57.1)	96(38.1)
	≥3	7(15.2)	68(29.6)	22(27.2)	119(29.6)	52(24.9)	197(31.5)	13(20.6)	64(25.4)
	n (%)	46(100.0)	230(100.0)	81(100.0)	402(100.0)	209(100.0)	626(100.0)	63(100.0)	252(100.0)
	Chi-square	8.03, df=3, p=.045		1.13, df=3, p=.769		4.00, df=3, p=.262		10.59, df=3, p=.014	
	Pregnancies(mean) [*]	1.46±0.93 ^a	2.01±1.43	1.90±1.28	1.91±1.39	1.78±1.20 ^a	2.10±1.53	1.97±0.98	2.01±1.30
	Age at 1 st pregnancy [*]	24.92±4.33	25.69±4.70	23.32±3.63 ^a	25.07±4.51	25.07±4.22	24.51±4.29	22.28±2.99	23.03±3.85

*: weighted according to the national population.

^a: p<0.05, t-test, comparison between users and controls in the same survey.

Data for survey BGS98 unavailable

Tables

Table 32: Blood pressure and hypertension for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Blood pressure	T0		T1		T2		T3		BGS98		
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls	
Contraceptives	Normal	219(84.9)	424(82.3)	276(78.4)	455(85.8)	271(82.6)	572(87.3)	213(70.3)	226(74.6)	517(83.4)	545(88.0)
	Hypertension¹	39(15.1)	91(17.7)	76(21.6)	75(14.2)	57(17.4)	83(12.7)	90(29.7)	77(25.4)	103(16.6)	74(12.0)
	n (%)	258(100.0)	515(100.0)	352(100.0)	530(100.0)	328(100.0)	655(100.0)	303(100.0)	303(100.0)	620(100.0)	619(100.0)
	Chi-square	.801, df=1, p=.371		8.25, df=1, p=.004		3.96, df=1, p=.046		1.40, df=1, p=.237		5.49, df=1, p=.019	
	SBP, mm Hg	121.6±14.2	121.6±16.2	124.7±15.6^b	120.7±14.8	123.7±16.4^b	120.4±13.3	126.8±16.1	125.8±15.9	123.8±14.8^b	120.2±13.7
	DBP, mm Hg	77.1±10.6	77.3±11.8	78.1±11.7^b	75.4±11.0	77.1±10.8	75.8±9.7	81.9±10.2	81.3±10.6	77.5±10.5^a	76.1±10.4
HRT	Anti-hyperten. medications	3.5%	5.1%	2.8%	2.5%	1.5%	1.8%	4.6%	4.3%	2.9%	3.1%
	Normal	26(56.5)	122(53.0)	44(54.3)	194(47.9)	102(48.6)	306(48.6)	24(38.1)	87(34.5)	202(47.4)	332(39.0)
	Hypertension¹	20(43.5)	108(47.0)	37(45.7)	211(52.1)	108(51.4)	323(51.4)	39(61.9)	165(65.5)	224(52.6)	520(61.0)
	n (%)	46(100.0)	230(100.0)	81(100.0)	405(100.0)	210(100.0)	629(100.0)	63(100.0)	252(100.0)	426(100.0)	852(100.0)
	Chi-square	.186, df=1, p=.666		1.113, df=1, p=.291		.000, df=1, p=.985		.282, df=1, p=.596		8.338, df=1, p=.004	
	SBP, mean	134.3±19.9	136.8±20.4	134.2±16.9	137.4±20.1	137.1±18.2	137.9±20.1	140.7±19.6	141.3±19.9	140.9±20.5^a	143.8±22.0
	DBP, mean	83.8±10.8	83.5±11.6	80.0±10.0^a	83.8±11.7	83.9±9.9	84.6±10.7	87.3±9.6	89.0±11.2	84.9±10.3	85.7±11.3
	Anti-hyperten. medications	17.8%	15.8%	16.3%	14.8%	18.1%	20.3%	21.7%	24.6%	23.2%^c	28.6%

SBP: Systolic blood pressure(mm Hg); DBP: diastolic blood pressure(mm Hg); The first and fifth Korotkoff sounds were recorded for the systolic and diastolic blood pressure, respectively.

¹: Hypertension, defined as a mean SPB≥140 mm Hg or a mean DBP≥90 mm Hg, or being prescribed anti-hypertension agents

^a: p<0.05, ^b: p<0.001, t-test, comparison between users and controls in the same survey. ^c: Chi-square test, p<0.05

Tables

Table 33: Blood fasting glucose concentration and diabetes for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Glucose	T0		T1		T2		T3		BGS98		
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls	
Contraceptives	Normal	238(97.1)	482(97.2)	336(96.8)	495(97.4)	316(97.5)	637(98.8)	295(97.4)	294(98.3)	588(98.8)	579(99.1)
	Diabetes¹	7(2.9)	14(2.8)	11(3.2)	13(2.6)	8(2.5)	8(1.2)	8(2.6)	5(1.7)	7(1.2)	5(0.9)
	n (%)	245(100.0)	496(100.0)	347(100.0)	508(100.0)	324(100.0)	645(100.0)	303(100.0)	299(100.0)	595(100.0)	584(100.0)
	Chi-square	.01, df=1, p=.979		.28, df=1, p=.595		2.0, df=1, p=.157		.67, df=1, p=.414		.30, df=1, p=.584	
	Anti-diabetic therapy	0%	.6%	.3%	.4%	.3%	.7%	0%	1.1%	.2%	.3%
HRT	Mean in serum mmol/l	5.236±.683	5.229±.762	5.203±1.00	5.151±1.17	5.058±.969	4.982±1.07	5.127±.694	5.199±1.19	4.982±.617	4.986±.631
	Normal	41(97.6)	196(91.2)	73(92.4)	362(92.8)	202(96.2)	569(91.5)	51(87.9)	218(92.0)	401(97.1)	725(90.3)
	Diabetes¹	1(2.4)	19(8.8)	6(7.6)	28(7.2)	8(3.8)	53(8.5)	7(12.1)	19(8.0)	12(2.9)	78(9.7)
	n (%)	42(100.0)	215(100.0)	79(100.0)	390(100.0)	210(100.0)	622(100.0)	58(100.0)	237(100.0)	413(100.0)	803(100.0)
	Chi-square	2.04, df=1, p=.153		.02, df=1, p=.897		5.13, df=1, p=.024		.952, df=1, p=.329		18.44, df=1, p=.000	
	Anti-diabetic therapy	0%	2.1%	1.1%	1.9%	.4%	2.4%	3.3%	2.6%	1.5%^b	4.4%
	Mean in serum mmol/l	5.422±.81	5.918±2.18	5.438±.83	5.638±1.66	5.201±.66^a	5.594±1.72	5.667±1.16	5.707±1.74	5.296±.74^a	5.752±1.78

¹: defined as fasting glucose >= 7 mmol/l or those under anti-diabetic therapy;

^a: p<0.001, t-test, comparison between users and controls in the same survey, ^b: p<0.05, chi-square test, comparison between users and controls in the same survey

Tables

Table 34: Blood uric acid and hyperuricemia (Gout) for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany*

Uric acid	T0		T1		T2		T3		BGS98		
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls	
Contraceptives	Normal	248(98.0)	485(95.8)	343(98.3)	482(96.8)	301(98.0)	583(97.0)	260(98.1)	263(97.4)	582(97.8)	575(98.5)
	Hyperuricemia¹	5(2.0)	21(4.2)	6(1.7)	16(3.2)	6(2.0)	18(3.0)	5(1.9)	7(2.6)	13(2.2)	9(1.5)
	n (%)	253(100.0)	506(100.0)	349(100.0)	498(100.0)	307(100.0)	601(100.0)	265(100.0)	270(100.0)	595(100.0)	584(100.0)
	Chi-square	2.41, df=1, p=.121		1.81, df=1, p=.179		.855, df=1, p=.355		.304, df=1, p=.581		.07, df=1, p=.414	
HRT	Mean in serum µmol/l	241.9±52.5	241.7±59.1	235±48.7	240.4±53.6	246.9±51.3	245.4±53	236±53.3	243±53.3	232.6±48.7	236±55.3
	Normal	48(96.0)	203(91.0)	81(95.3)	376(92.8)	205(92.3)	565(89.5)	55(94.8)	216(91.1)	399(96.6)	706(87.9)
	Hyperuricemia¹	2(4.0)	20(9.0)	4(4.7)	29(7.2)	17(7.7)	66(10.5)	3(5.2)	21(8.9)	14(3.4)	97(12.1)
	n (%)	50(100.0)	223(100.0)	85(100.0)	405(100.0)	222(100.0)	631(100.0)	58(100.0)	237(100.0)	413(100.0)	803(100.0)
	Chi-square	1.36, df=1, p=.243		.674, df=1, p=.412		1.47, df=1, p=.226		.848, df=1, p=.357		24.83, df=1, p=.000	
	Mean in serum µmol/l	249.2±53.4	265.3±67.6	257.8±60.2	258.6±69.5	267.7±62.3	275.8±70.5	262.1±58.2	265.8±61.2	254.2±59.1^a	276.8±74.3

*: All data were weighted according to national population;

¹: defined as uric acid >= 357 µmol/l or those under anti-diabetic therapy;

^a: p<0.001, t-test, comparison between users and controls in the same survey

Tables

Table 35: Blood lipids and hyperlipidemia for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany*

Lipids mmol/l	T0		T1		T2		T3		BGS98		
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls	
Contraceptives	Normal	74(29.4)	209(41.2)	120(34.4)	209(41.9)	86(28.0)	232(38.5)	99(32.7)	96(32.1)	229(38.5)	270(46.2)
	Hyperlipidemia¹	178(70.6)	298(58.8)	229(65.6)	290(58.1)	221(72.0)	370(61.5)	204(67.3)	203(67.9)	366(61.5)	314(53.8)
	n (%)	252(100.0)	507(100.0)	349(100.0)	499(100.0)	307(100.0)	602(100.0)	303(100.0)	299(100.0)	595(100.0)	584(100.0)
	Chi-square	10.12, df=1, p=.001		4.87, df=1, p=.027		9.90, df=1, p=.002		.022, df=1, p=.882		7.24, df=1, p=.007	
	Lipd-lwr ther.	0%	.2%	0%	.4%	.3%	.8%	0%	.4%	.2%	.5%
	Ttl-C	5.508±1.03	5.424±1.10	5.372±.939	5.400±1.03	5.641±.945^a	5.467±.999	5.518±.925	5.579±.953	5.446±.939^a	5.331±1.04
	Triglycerides	1.549±.714^a	1.425±.871	1.612±.667^b	1.366±.801	1.597±.738^b	1.327±.780	1.586±.789	1.500±.927	1.257±.605^b	1.086±.706
	HDL-C	1.700±.438	1.686±.417	1.656±.433	1.649±.426	1.826±.461^a	1.732±.432	1.794±.419	1.725±.429	1.715±.415^b	1.619±.445
HRT	LDL-C	3.112±.974	3.091±.968	2.985±.908^a	3.123±.884	3.088±.831	3.136±.915	3.018±.881	3.137±.900	3.159±.834	3.218±.869
	HDL-C/Ttl-C	.316±.088	.321±.936	.315±.089	.312±.083	.330±.090	.325±.087	.333±.093	.318±.090	.320±.086^a	.309±.081
	Normal	3(6.1)	8(3.6)	19(22.4)	49(12.1)	11(5.0)	58(9.2)	8(13.1)	32(12.7)	50(12.1)	73(9.1)
	Hyperlipidemia¹	46(93.9)	215(96.4)	66(77.6)	356(87.9)	211(95.0)	574(90.8)	53(86.9)	220(87.3)	363(87.9)	730(90.9)
	n (%)	49(100.0)	223(100.0)	85(100.0)	405(100.0)	222(100.0)	632(100.0)	61(100.0)	252(100.0)	413(100.0)	803(100.0)
	Chi-square	.67, df=1, p=.415		6.18, df=1, p=.013		3.94, df=1, p=.047		.01, df=1, p=.930		2.73, df=1, p=.099	
	Lipid-lwr ther.	3.8%	4.2%	2.3%	3.1%	5.9%	4.2%	1.7%	3.4%	6.2%	5.7%
	Ttl C	6.497±1.15	6.746±1.22	6.087±1.21^a	6.475±1.27	6.359±1.01^a	6.569±1.20	6.528±1.40	6.486±1.23	6.342±1.10^b	6.579±1.21
	Triglycerides	1.683±.916	1.942±1.04	1.720±.970	1.853±1.11	1.757±.876	1.871±1.05	1.890±1.07	1.834±.890	1.389±.749^b	1.588±.965
	HDL-C	1.999±.633^b	1.608±.401	1.693±.457	1.645±.436	1.786±.493	1.728±.495	1.728±.535	1.711±.435	1.754±.494^b	1.638±.470
	LDL-C	3.767±1.22^a	4.232±1.16	3.605±1.01^a	3.987±1.13	3.778±.932^a	3.976±1.12	3.937±1.41	3.923±1.10	3.957±1.01^b	4.219±1.06
	HDL-C/Ttl-C	.316±.118^b	.247±.072	.286±.077^a	.261±.080	.285±.080^a	.272±.089	.275±.097	.273±.085	.282±.082^b	.254±.077

*: All data were weighted according to national population;

¹: defined as total cholesterol concentration in serum >=5.2 mmol/l or triglycerides concentration >=1.7 mmol/l or those undergoing lipid-lowering therapy (lipid-lwr ther). Ttl-C: total cholesterol, HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol;

^a: p<.05; ^b: p<.001, t-test, comparison between users and controls in the same survey..

Tables

Table 36: Number of clinical contacts ('visiting a doctor') in the last 4 weeks for every 100 steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

	In the last 4 weeks visiting a...	T0		T1		T2		T3		BGS98	
		Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	General Practitioner	21.3	22.9	24.9	19.8	22.0	23.3	25.7	22.1	16.3	16.9
	Physician	5.0	8.0	3.7	5.5	4.6	5.8	1.3	3.6	1.3	2.3
	Gynecologist	20.9	18.8	14.7	19.1	20.0	16.2	20.1	17.2	9.2	11.6
	Others	16.0	15.2	13.1	16.3	16.4	20.0	15.2	13.6	9.4	10.1
	<i>Oculist</i>	1.9	2.3	2.0	2.8	3.4	2.6	1.3	3.0	0.7	0.7
	<i>Orthopedist</i>	3.5	2.1	2.0	2.1	2.7	4.0	1.3	1.3	2.3	2.3
	<i>Otorhinolaryngologist</i>	2.3	2.5	2.8	2.3	3.0	3.1	2.6	2.0	1.1	0.7
	<i>Neurologist, psychiatrist</i>	1.2	1.0	1.7	1.1	0.6	2.3	1.0	0.3	1.0	1.6
	<i>Surgeon</i>	1.2	1.4	0.3	0.8	0.6	1.5	1.7	0.7	1.3	1.5
	<i>Dermatologist</i>	3.9	2.5	2.3	4.7	4.0	3.7	4.0	3.0	2.3	2.3
	<i>Radiologist</i>	1.2	1.7	1.4	1.7	1.5	2.0	2.3	2.3	0.5	0.5
	<i>Urologist</i>	0.8	1.7	0.6	0.8	0.6	0.8	1.0	1.0	0.2	0.5
HRT	Chi-square test*	.884, df=3, p=.829		1.60, df=3, p=.659		.971, df=3, p=.808		2.21, df=3, p=.531		.373, df=3, p=.946	
	General Practitioner	45.7	37.8	32.1	31.9	32.9	35.4	44.4	38.1	23.9	24.9
	Physician	19.6	16.5	11.1	9.6	18.6	9.8	9.5	5.6	11.5	6.9
	Gynecologist	13.0	5.2	29.6	10.1	33.3	9.1	22.2	9.1	8.9	2.6
	Others	10.9	26.9	29.7	20.0	38.2	20.7	19.1	21.6	15.5	11.2
	<i>Oculist</i>	0	7.4	3.7	3.2	7.6	4.8	1.6	4.0	0.9	1.2
	<i>Orthopedist</i>	6.5	7.4	6.2	4.9	12.4	5.2	1.6	2.0	7.3	3.5
	<i>Otorhinolaryngologist</i>	0	1.3	4.9	3.0	5.2	1.4	1.6	1.2	0.9	1.4
	<i>Neurologist, psychiatrist</i>	0	2.6	2.5	2.7	4.8	1.0	1.6	0.8	1.9	1.2
	<i>Surgeon</i>	0	1.3	3.7	0.7	0	1.4	0	4.4	1.2	1.2
	<i>Dermatologist</i>	2.2	3.9	6.2	2.7	4.8	2.9	7.9	2.8	0.9	1.4
	<i>Radiologist</i>	2.2	2.6	2.5	2.5	2.4	2.9	3.2	5.6	1.2	1.1
	<i>Urologist</i>	0	0.4	0	0.3	1.0	1.11	1.6	0.8	1.2	0.2
	Chi-square test*	11.25, df=3, p=.010		6.77, df=3, p=.080		10.44, df=3, p=.015		4.82, df=3, p=.185		3.22, df=3, p=.359	

*: Testing difference among 'General practitioner', 'Physician', 'Gynecologist' and 'others' only.

Tables

Table 37: Hospitalization and average days in hospital during last 12 months for steroid hormone users and controls in the five National Health Surveys from 1984 to 1999 in Germany

	Hospitalization in the last 12 months	T0		T1		T2		T3		BGS98	
		Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Contraceptives	No	229(89.5)	437(85.0)	309(88.0)	452(85.3)	282(86.2)	553(84.4)	286(94.4)	263(86.8)	551(89.6)	497(82.1)
	Yes	27(10.5)	77(15.0)	42(12.0)	78(14.7)	45(13.8)	102(15.6)	17(5.6)	40(13.2)	6410.4	108(17.9)
	n(%)	256(100.0)	514(100.0)	351(100.0)	530(100.0)	327(100.0)	655(100.0)	303(100.0)	303(100.0)	615(100)	605(100)
	Chi-square	2.88, df=1, P=.090		1.34, df=1, P=.244		.56, df=1, p=.453		10.24, df=1, p=.001		13.96, df=1, p=.000	
HRT	Average days in hospitals	10.7±8.7	11.1±14.7	8.1±6.0	9.8±12.2	6.6±4.3^a	9.6±10.8	6.4±4.2^a	12.2±9.2	8.8±8.7	10.3±16.4
	No	42(91.3)	198(86.1)	77(95.1)	362(89.4)	183(87.6)	572(91.1)	48(77.4)	230(91.3)	374(88.0)	722(87.3)
	Yes	4(8.7)	32(13.9)	4(4.9)	43(10.6)	26(12.4)	56(8.9)	14(22.6)	22(8.7)	51(12.0)	105(12.7)
	n(%)	46(100.0)	230(100.0)	81(100.0)	405(100.0)	209(100.0)	628(100.0)	62(100.0)	252(100.0)	425(100)	827(100)
	Chi-square	.92, df=1, p=.337		2.49, df=1, p=.114		2.20, df=1, p=.138		9.40, df=1, p=.002		.125, df=1, p=.724	
	Average days in hospital	25.5±33.4	12.8±8.6	11.8±4.8	18.5±31.1	14.5±11.1	16.2±17.1	33.4±77.2	19.4±20.7	14.0±14.1	15.5±18.3

^a: p<.05; t-test, comparison between users and controls in the same survey.

Tables

Table 38: Multi-medications in the last 7 days for contraceptive users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Co-medications	T0		T1		T2		T3		BGS98	
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
A00*	46 (17.8)	149 (28.9)	49 (13.9)	85 (16.0)	57 (17.4)	134 (20.4)	21 (6.9)	25 (8.3)	148 (23.9)	164 (26.5)
A02	6 (2.3)	24 (4.7)	5 (1.4)	10 (1.9)	7 (2.1)	17 (2.6)	3 (1.0)	2 (0.7)	14 (2.3)	7 (1.1)
A06	6 (2.3)	18 (3.5)	8 (2.3)	15 (2.8)	4 (1.2)	9 (1.4)	0 (0)	0 (0)	2 (0.3)	1 (0.2)
A10	0 (0)	3 (0.6)	1 (0.3)	3 (0.6)	2 (0.6)	3 (0.5)	0 (0)	5 (1.6)	3 (0.5)	5 (0.8)
A11	18 (7.0)	50 (9.7)	15 (4.3)	27 (5.1)	26 (7.9)	51 (7.8)	8 (2.6)	5 (1.6)	55 (8.9)	67 (10.8)
A12	8 (3.1)	19 (3.7)	7 (2.0)	13 (2.5)	6 (1.8)	25 (3.8)	1 (0.3)	2 (0.7)	29 (4.7)	49 (7.9)
A13	2 (0.8)	6 (1.2)	2 (0.6)	4 (0.8)	1 (0.3)	1 (0.1)	1 (0.3)	2 (0.7)	14 (2.3)	6 (1.0)
B00	5 (1.9)	19 (3.7)	2 (0.6)	13 (2.5)	10 (3.0)	22 (3.4)	2 (0.7)	8 (2.6)	12 (1.9)	23 (3.7)
C00*	31 (12.0)	90 (17.4)	37 (10.5)	63 (11.9)	20 (6.1)	56 (8.5)	30 (9.9)	27 (8.9)	43 (6.9)	46 (7.4)
C01	14 (5.4)	26 (5.0)	12 (3.4)	24 (4.5)	8 (2.4)	19 (2.9)	9 (3.0)	6 (2.0)	9 (1.45)	14 (2.3)
C02	1 (0.4)	4 (0.8)	1 (0.3)	2 (0.4)	0 (0)	1 (0.1)	0 (0)	0 (0)	1 (0.2)	0 (0)
C03	3 (1.2)	15 (2.9)	6 (1.7)	5 (0.9)	2 (0.6)	6 (0.9)	0 (0)	3 (1.0)	3 (0.5)	7 (1.1)
C04	1 (0.4)	6 (1.2)	1 (0.3)	3 (0.6)	2 (0.6)	2 (0.3)	3 (1.0)	1 (0.3)	1 (0.2)	1 (0.2)
C05	4 (1.6)	9 (1.7)	4 (1.1)	11 (2.1)	4 (1.2)	7 (1.1)	2 (0.7)	0 (0)	6 (1.0)	6 (1.0)
C07	6 (2.3)	20 (3.9)	6 (1.7)	11 (2.1)	2 (0.6)	10 (1.5)	14 (4.6)	10 (3.3)	13 (2.1)	14 (2.3)
C08	0 (0)	3 (0.6)	0 (0)	1 (0.2)	0 (0)	1 (0.1)	2 (0.7)	4 (1.3)	3 (0.5)	0 (0)
D00	20 (7.8)	50 (9.7)	15 (4.3)	30 (5.7)	14 (4.3)	64 (9.8)	10 (3.3)	17 (5.6)	49 (7.9)	46 (7.4)
G00	261 (101)	22 (4.3)	361 (102)	15 (2.8)	333 (101)	17 (2.6)	310 (102)	12 (4.0)	630 (102)	25 (4.0)
H00	23 (8.9)	45 (8.7)	28 (7.9)	55 (10.4)	21 (6.4)	54 (8.2)	13 (4.3)	27 (8.9)	46 (7.4)	64 (10.3)
J00	8 (3.1)	6 (1.2)	5 (1.4)	11 (2.1)	5 (1.5)	12 (1.8)	7 (2.3)	5 (1.7)	17 (2.7)	16 (2.6)
L00	0 (0)	1 (0.2)	0 (0)	3 (0.6)	0 (0)	2 (0.3)	0 (0)	0 (0)	17 (2.7)	51 (8.2)
M00	8 (3.1)	31 (6.0)	11 (3.1)	13 (2.5)	8 (2.4)	29 (4.4)	12 (4.0)	17 (5.6)	45 (7.3)	54 (8.7)
N00*	61 (23.6)	121 (23.4)	61 (17.3)	54 (10.2)	47 (14.3)	100 (15.2)	60 (19.8)	65 (21.5)	173 (27.9)	174 (28.1)
N02	44 (17.1)	81 (15.7)	45 (12.7)	36 (6.8)	37 (11.3)	71 (10.8)	51 (16.8)	48 (15.8)	146 (23.5)	120 (19.4)
N05	14 (5.4)	33 (6.4)	4 (1.1)	13 (2.5)	5 (1.5)	13 (2.0)	4 (1.3)	11 (3.6)	10 (1.6)	21 (3.4)
N06	2 (0.8)	4 (0.8)	8 (2.3)	2 (0.4)	3 (0.9)	7 (1.1)	4 (1.3)	1 (0.3)	14 (2.3)	22 (3.6)
P00	2 (0.8)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.2)	0 (0)	0 (0)	0 (0)	0 (0)

Tables

R00*	37 (14.3)	85 (16.5)	30 (8.5)	39 (7.4)	41 (12.5)	65 (9.9)	37 (12.2)	47 (15.5)	119 (19.2)	88 (14.2)
<i>R03</i>	7 (2.7)	12 (2.3)	3 (0.8)	11 (2.1)	13 (4.9)	14 (2.1)	12 (4.0)	12 (4.0)	21 (3.4)	15 (2.4)
<i>R05</i>	15 (5.8)	33 (6.4)	10 (2.8)	15 (2.8)	10 (3.0)	26 (4.0)	10 (3.3)	18 (5.9)	48 (7.7)	42 (6.8)
S00	6 (2.3)	5 (1.0)	4 (1.1)	7 (1.3)	0 (0)	3 (0.5)	2 (0.7)	4 (1.3)	19 (3.1)	11 (1.8)
V00	2 (0.8)	32 (6.2)	10 (2.8)	16 (3.0)	5 (1.5)	34 (5.2)	2 (0.7)	4 (1.3)	47 (7.6)	28 (4.5)
Z00	4 (1.6)	12 (2.3)	2 (0.6)	7 (1.3)	4 (1.2)	7 (1.1)	1 (0.3)	2 (0.7)	5 (0.8)	7 (1.1)
Total drug use	514 (199)	668 (129)	615 (174)	411 (77.5)	565 (172)	600 (91.5)	507 (167)	260 (85.8)	1370 (221)	797 (129)
Chi-square	26.21, df=11, p=.006		18.26, df=11, p=.076		18.07, df=11, p=.080		9.35, df=11, p=.590		20.19, df=11, p=.043	

() : drug uses in every 100 contraceptive users or controls;

*: not all subgroup drug uses under this group were listed;

**: testing difference not including L00, P00 and all subgroups ;

A00: Alimentary tract and metabolism;

 A02:Antacids, drugs for treatment of peptic ulcer and flatulence; A06: Laxatives; A10: Drug used in diabetics; A11: Vitamins; A12: Mineral supplements; A13: Tonics

B00: Blood and blood forming organs;

C00: Cardiovascular system;

 C01: Cardiac therapy; C02: Anti-hypertensives; C03:Diuretics; C04: Peripheral vasodilators; C05: Vasoprotectives; C07: Beta blocking agents;
 C08: Calcium channel blockers;

D00: Dermatologicals;

G00: Genito urinary system and sex hormones;

H00: Systemic hormonal preparations, exclu. Sex hormones and insulin;

J00: Antiinfectives for systemic use;

L00: Antineoplastic and immunomodulating agents;

M00: Musculo-skeletal system;

N00: Nervous system;

 N02:Analgesics; N05: Psycholeptics; N06: Psychoanaleptics;

P00: Antiparastic products, insecticides and repellents;

R00: Respiratory system;

 R03: Anti-asthmatics; R05: Cough and cold preparations.

S00: Sensory organs; **V00:** Various; **Z00:** Homeopathic agents;

Tables

Table 39: Multi-medications in the last 7 days for HRT users and controls in the five National Health Surveys from 1984 to 1999 in Germany

Co-medications	T0		T1		T2		T3		BGS98	
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
A00*	28 (60.9)	86 (37.4)	42 (51.9)	143 (35.3)	97 (46.2)	213 (33.8)	18 (28.6)	62 (24.6)	326 (76.3)	505 (59.1)
A02	2 (4.3)	9 (3.9)	7 (8.6)	22 (5.4)	13 (6.2)	34 (5.4)	3 (4.8)	8 (3.2)	37 (8.7)	40 (4.7)
A06	6 (13.0)	13 (5.6)	6 (7.4)	25 (6.2)	9 (4.3)	24 (3.8)	1 (1.6)	2 (0.8)	12 (2.8)	17 (2.0)
A10	0 (0)	5 (2.2)	1 (1.2)	8 (2.0)	1 (0.5)	18 (2.9)	2 (3.2)	8 (3.2)	13 (3.0)	65 (7.6)
A11	7 (15.2)	15 (6.5)	8 (9.9)	21 (5.2)	26 (12.4)	51 (8.1)	5 (7.9)	13 (5.2)	118 (27.6)	138 (16.2)
A12	5 (10.9)	14 (6.1)	8 (9.9)	24 (5.9)	28 (13.3)	39 (6.2)	3 (4.8)	5 (2.0)	82 (19.2)	137 (16.0)
A13	4 (8.7)	10 (4.3)	4 (4.9)	11 (2.7)	1 (0.5)	5 (0.8)	1 (1.6)	3 (1.2)	17 (4.0)	35 (4.1)
B00	1 (2.2)	26 (11.3)	15 (18.5)	31 (7.7)	23 (11.0)	57 (9.1)	1 (1.6)	18 (7.1)	35 (8.2)	48 (5.6)
C00*	32 (69.6)	163 (70.9)	57 (70.4)	195 (48.1)	123 (58.6)	331 (52.5)	36 (57.1)	148 (58.7)	254 (59.5)	601 (70.4)
C01	9 (19.6)	51 (22.2)	15 (18.5)	45 (11.1)	19 (9.0)	61 (9.7)	10 (15.9)	30 (11.9)	35 (8.2)	103 (12.1)
C02	3 (6.5)	15 (6.5)	4 (4.9)	15 (3.7)	5 (2.4)	18 (2.7)	4 (6.3)	6 (2.4)	7 (1.6)	25 (2.9)
C03	1 (2.2)	14 (6.1)	8 (9.9)	18 (4.4)	14 (6.7)	38 (6.0)	1 (1.6)	20 (7.9)	20 (4.7)	66 (7.7)
C04	8 (17.4)	20 (8.7)	8 (9.9)	24 (5.9)	15 (7.1)	28 (4.4)	1 (1.6)	12 (4.8)	3 (0.7)	8 (0.9)
C05	3 (6.5)	22 (9.6)	6 (7.4)	21 (5.2)	20 (9.5)	39 (6.2)	1 (1.6)	11 (4.6)	26 (6.1)	47 (5.5)
C07	3 (6.5)	17 (7.4)	7 (8.6)	35 (8.6)	27 (12.9)	58 (9.2)	14 (22.2)	40 (15.9)	66 (15.5)	118 (13.8)
C08	3 (6.5)	13 (5.6)	4 (4.9)	17 (4.2)	10 (4.8)	42 (6.7)	4 (6.3)	26 (10.3)	25 (5.9)	73 (8.5)
D00	2 (4.4)	8 (3.5)	2 (2.5)	12 (3.0)	14 (6.7)	30 (4.8)	1 (1.6)	9 (3.6)	41 (9.6)	68 (8.0)
G00	46 (100)	10 (4.4)	83 (102)	16 (4.9)	221 (105)	22 (3.5)	73 (116)	3 (1.2)	464 (109)	47 (5.5)
H00	9 (19.6)	24 (10.4)	9 (11.1)	48 (11.9)	34 (16.2)	66 (10.5)	11 (17.5)	22 (8.7)	77 (18.0)	136 (15.9)
J00	0 (0)	3 (1.3)	0 (0)	4 (1.0)	4 (1.9)	8 (1.3)	2 (3.2)	4 (1.6)	19 (4.5)	16 (1.9)
L00	0 (0)	4 (1.7)	0 (0)	3 (0.7)	0 (0)	1 (0.2)	0 (0)	0 (0)	20 (4.7)	39 (4.6)
M00	9 (19.6)	35 (15.2)	12 (14.8)	38 (9.4)	36 (17.1)	77 (12.2)	6 (9.5)	26 (10.3)	99 (23.2)	150 (17.6)
N00*	24 (52.2)	82 (35.7)	29 (35.8)	96 (23.7)	56 (26.7)	158 (25.1)	34 (54.0)	82 (32.5)	204 (47.8)	351 (41.1)
N02	11 (23.9)	34 (14.8)	10 (12.3)	43 (10.6)	23 (11.0)	80 (12.7)	14 (22.2)	40 (15.9)	93 (21.8)	172 (20.1)
N05	12 (26.1)	38 (16.5)	11 (13.6)	34 (8.4)	23 (11.0)	48 (7.6)	15 (23.8)	22 (8.7)	42 (9.8)	60 (7.0)
N06	1 (2.2)	9 (3.9)	8 (9.9)	13 (3.2)	8 (3.8)	24 (3.8)	2 (3.2)	7 (2.8)	45 (10.5)	82 (9.6)
P00	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.5)	1 (0.2)	0 (0)	0 (0)	2 (0.5)	1 (0.1)
R00*	1 (2.2)	36 (15.7)	9 (11.1)	40 (9.9)	36 (17.1)	73 (11.6)	13 (20.6)	30 (11.9)	102 (23.9)	144 (16.9)

Tables

<i>R03</i>	<i>1</i> (2.2)	<i>11</i> (4.8)	<i>1</i> (1.2)	<i>15</i> (3.7)	<i>12</i> (5.7)	<i>18</i> (2.9)	<i>3</i> (4.8)	<i>7</i> (2.8)	<i>35</i> (8.2)	<i>43</i> (5.0)
<i>R05</i>	<i>0</i> (0)	<i>18</i> (7.8)	<i>4</i> (4.9)	<i>15</i> (3.7)	<i>14</i> (6.7)	<i>32</i> (5.1)	<i>5</i> (7.9)	<i>22</i> (8.7)	<i>43</i> (10.1)	<i>67</i> (7.8)
S00	1 (2.2)	9 (3.9)	2 (2.5)	6 (1.5)	10 (4.8)	11 (1.8)	1 (1.6)	6 (2.4)	32 (7.5)	38 (4.5)
V00	3 (6.5)	13 (5.7)	2 (2.5)	10 (2.5)	17 (8.1)	41 (6.5)	2 (3.2)	6 (2.4)	24 (5.6)	70 (8.2)
Z00	2 (4.4)	9 (3.9)	3 (3.7)	7 (1.7)	5 (2.4)	4 (0.6)	2 (3.2)	1 (0.4)	1 (0.2)	8 (0.9)
Total drug use	158 (343)	508 (221)	265 (327)	649 (160)	677 (322)	1093 (173)	200 (317)	417 (165)	1700 (398)	2222 (260)
Chi-square **	17.83, df=11, p=.086	6.76, df=11, p=.818		11.48, df=11, p=.404		15.10, df=10, p=.128		34.67, df=11, p=.000		

(): drug uses in every 100 HRT users or controls;

*: not all subgroup drug uses under this group were listed;

**: testing difference not including L00, P00 and all subgroups ;

A00: Alimentary tract and metabolism;

 A02:Antacids, drugs for treatment of peptic ulcer and flatulence; A06: Laxatives; A10: Drug used in diabetics; A11: Vitamins; A12: Mineral supplements; A13: Tonics

B00: Blood and blood forming organs;

C00: Cardiovascular system;

 C01: Cardiac therapy; C02: Anti-hypertensives; C03:Diuretics; C04: Peripheral vasodilators; C05: Vasoprotectives; C07: Beta blocking agents; C08: Calcium channel blockers;

D00: Dermatologicals;

G00: Genito urinary system and sex hormones;

H00: Systemic hormonal preparations, exclu. Sex hormones and insulin;

J00: Antiinfectives for systemic use;

L00: Antineoplastic and immunomodulating agents;

M00: Musculo-skeletal system;

N00: Nervous system;

 N02:Analgesics; N05: Psycholeptics; N06: Psychoanaleptics;

P00: Antiparastic products, insecticides and repellents;

R00: Respiratory system;

 R03: Anti-asthmatics; R05: Cough and cold preparations.

S00: Sensory organs; V00, Various; Z00: Homeopathic agents;

Tables

Table 40: Laboratory measurements for contraceptive users and controls in the five National Health Surveys from 1984 to 1999 in Germany*

	T0		T1		T2		T3		BGS98	
	Users	Controls								
Na, mmol/l	140.2±4.2	140.3±3.5	140.6±1.8	140.6±2.1	141.1±2.1	140.9±2.6	140.3±2.3	140.3±2.3	Data unavailable	
K, mmol/l	3.876±.34	3.882±.35	3.930±.33	3.936±.37	4.170±.36	4.140±.39	4.125±.37	4.088±.32	4.000±.32	3.978±.30
Cl, mmol/l	105.1±2.6	104.8±2.9	106.6±2.31	106.3±2.37	106.9±2.29	106.5±2.54	103.6±2.35	103.5±2.56	Data unavailable	
P(anorg.), mmol/l	0.978±.16^b	1.055±.16	1.036±.18^a	1.128±.17	1.065±.16^b	1.143±.17	1.022±.16^b	1.100±.16	Data unavailable	
Ca, mmol/l	2.321±.10^a	2.338±.12	2.369±.09^a	2.387±.10	2.435±.08	2.446±.10	2.427±.09^a	2.451±.09	2.346±.09	2.355±.10
Fe, µmol/l	20.1±10.0^b	17.3±8.0	19.05±7.8^a	17.26±7.2	18.36±7.9^b	16.13±7.3	17.65±7.5^a	15.62±8.3	18.03±7.0^b	15.25±6.8
Mg, mmol/l	0.864±.07	0.869±.07	0.937±.07	0.942±.07	0.855±.07	0.848±.07	0.834±.06	0.833±.05	0.837±.06	0.844±.06
WBC, 1/nl	7.960±2.22	7.900±2.17	7.644±2.02	7.384±2.02	7.667±1.87	7.538±1.85	7.652±2.12	7.938±2.15	7.720±2.16	7.656±2.19
RBC, 1/pl	4.490±.35	4.500±.40	4.478±0.36	4.475±0.35	4.421±0.31	4.464±0.32	4.403±.28^a	4.486±.36	4.339±.30	4.372±.32
Haemoglobin, g/l	135.0±10.3	135.3±10.5	136.3±9.7	135.2±10.1	136.3±8.9	137±10.0	134.9±9.1^a	137.3±10.2	133.8±8.6	133.6±10.9
Ferritin, µg/l	Data unavailable		54.5±55.4^b	42.1±49.2	57.7±62.4^b	43.09±41.8	60.54±55.8	54.28±75.4	42.0±32.5^b	33.2±33.4
Transferrin, g/l	Data unavailable		3.647±.62^b	3.244±.65	3.514±.59^b	3.107±.61	3.476±.60^b	3.005±.49	3.293±.57^b	2.904±.49
MCV, fl	90.05±4.3	89.88±4.9	91.86±5.2	91.43±4.8	89.34±3.9	89.03±4.4	90.83±4.0	90.54±4.0	91.23±4.0^a	90.44±5.2
MCH, pg	Data unavailable		31.33±1.3^a	30.88±1.8	30.95±1.7	30.79±1.9	30.66±1.6	30.66±1.5	30.88±1.6^a	30.62±2.1
MCHC, g/l	Data unavailable		337.5±9.6	337.1±9.7	345.2±14.1	344.4±12.9	337.5±7.6	338.5±7.3	338.4±7.9	338.4±8.5
Albumin, g/l	44.55±2.6^b	46.15±2.9	45.66±2.2^b	47.2±2.9	45.83±2.5^b	46.93±2.9	46.43±2.4^b	47.99±2.8	47.44±2.2^b	48.64±2.6
Total Album, g/l	71.53±4.2	71.92±4.2	71.79±3.9^a	72.40±4.2	72.34±3.8	72.35±4.4	73.39±3.8	73.86±4.2	73.76±4.0	74.05±4.3
Bilirubin, µmol/l	5.99±2.85^a	6.69±3.75	5.90±2.73^b	7.57±4.84	6.71±4.02^a	7.48±4.04	5.99±2.78^b	8.04±6.01	Data unavailable	
Cholinesterase	7.66±1.5^b	8.74±1.9	7.243±1.4^b	8.00±1.8	7.36±1.5^b	7.94±1.69	7.11±1.4^a	8.18±1.61	Data unavailable	
Thiocyanate,	78.8±53.9^a	69.7±45.9	91.1±60.1	87.6±56.5	80.8±57.2	79.1±52.7	77.3±50.8^a	86.4±56.3	Data unavailable	
BUN, mmol/l	4.35.19	4.46.55	4.55±1.06	4.66±1.53	4.45±1.10	4.35±1.30	4.21±1.03^a	4.40±1.12	Data unavailable	
Creatinine, µmol/l	73.56±14.2	73.34±35.1	71.5±11.2^a	68.9±14.4	72.26±11.4	71.26±26.1	72±10.6	70.12±12.8	Data unavailable	
Gamma-GT, U/l	Data unavailable		13.77±42.4	11.14±10.7	14.68±30.3	11.55±10.4	11.13±7.6	11.95±26.8	10.91±10.4	12.03±19.2

All values in the table were weighted according to national population. For blood concentrations of glucose, uric acid and lipids, please refer to Tables 33, 34 and 35, respectively

^a: p<.05; ^b: p<.001 t-test, comparison between users and controls in the same survey.

Tables

Table 41: Laboratory measurements for HRT users and controls in the five National Health Surveys from 1984 to 1999 in Germany*

	T0		T1		T2		T3		BGS98	
	Users	Controls	Users	Controls	Users	Controls	Users	Controls	Users	Controls
Na, mmol/l	141.1±3.22	141.9±3.06	141.3±1.75	141.1±2.33	141.3±2.43	141.3±2.5	140.5±2.28	140.8±2.51	Data unavailable	
K, mmol/l	4.034±.52	3.921±.37	3.997±.32	4.01±.34	4.288±.42	4.226±.40	4.219±.33	4.171±.32	4.109±.38	4.099±.36
Cl, mmol/l	104.6±3.18	104.7±3.35	106.5±2.0^a	105.9±2.48	106.2±2.55	106±2.95	103.1±3.42	103.3±2.97	Data unavailable	
P(anorg.), mmol/l	1.021±.19^a	1.09±.17	1.055±.17^a	1.106±.16	1.065±.16^b	1.124±.16	1.034±.17^a	1.102±.16	Data unavailable	
Ca, mmol/l	2.346±.08	2.359±.11	2.388±.08	2.405±.10	2.452±0.1	2.458±0.1	2.426±.10	2.45±.10	2.344±.11^b	2.372±.11
Fe, µmol/l	17.53±5.38	17.32±5.39	16.93±5.9	16.91±6.05	17.08±6.1^b	15.35±5.78	15.34±5.94	14.6±6.82	17.39±6.3^b	16.1±6.41
Mg, mmol/l	0.936±.15	0.898±.08	0.954±.06	0.952±.06	0.857±.07	0.856±.07	0.851±.07	0.858±.06	0.861±.06	0.859±.07
WBC, 1/l	6.851±1.72	7.116±2.03	7.157±1.88	6.972±1.89	6.912±1.59	7.038±1.74	7.427±2.48	7.239±2.24	7.346±2.0^a	7.055±2.01
RBC, 1/pl	4.478±.50^a	4.665±.43	4.503±.34^a	4.583±.36	4.45±.33^b	4.553±.36	4.503±.29	4.534±.30	4.369±.32^b	4.438±.33
Haemoglobin, g/l	134.6±13.2^a	139.9±10.7	137.6±11.2	138.5±10.6	138.0±8.86^a	139.7±11.1	139±9.94	138.1±9.94	137.0±8.67	137.4±10.1
Ferritin, µg/l	Data unavailable		89.35±93.5	88.72±99.6	84.0±77.0	89.3±86.2	89.55±80.4	99.74±86.7	77.1±59.3^b	91.67±85.9
Transferrin, g/l	Data unavailable		3.215±.57	3.189±.58	3.133±.56	3.089±.53	3.025±.62	2.961±.50	2.789±.45	2.781±.43
MCV, fl	91.6±3.26^a	90.14±4.51	91.47±4.7	91.24±4.92	89.99±4.59	89.28±4.63	91.4±3.58	90.43±4.52	93.0±4.5^b	91.79±4.94
MCH, pg	Data unavailable		31.3±2.16	31.14±1.46	31.1±1.79^a	30.74±2.02	30.88±1.36	30.5±1.75	31.4±1.6^b	31.03±1.81
MCHC, g/l	Data unavailable		336.1±9.94	337.6±9.53	344.5±11.6	343±14.4	337.9±7.08	337.2±7.68	337.7±7.54	338±7.92
Albumin, g/l	45.66±2.57	45.61±2.83	46.34±2.54	46.72±2.45	46.16±2.3^a	46.56±2.84	46.47±2.4^a	47.33±2.55	47.37±2.2^a	47.79±2.38
Total Album, g/l	72.19±3.87	72.25±4.7	71.97±3.77	72.32±4.09	72.14±4.08	72.57±4.21	72.67±4.29	73.6±4.28	72.93±4.2^b	73.91±4.22
Bilirubin, µmol/l	5.558±2.36	6.169±2.72	7.128±4.82	6.907±3.41	7.1±3.16	6.898±3.26	6.512±3.32	6.918±3.45	Data unavailable	
Cholinesterase	9.31±1.77^a	10.27±2.33	8.45±1.96^a	9.082±2.09	8.758±1.9^b	9.476±2.12	8.782±2.06	9.239±2.07	Data unavailable	
Thiocyanate,	48.34±30.8^a	63.96±43	74.54±44.5	79.67±54.9	66.96±46.8	73.44±49.2	66.39±48	73.93±50.2	Data unavailable	
BUN, mmol/l	6.043±2.85^a	5.461±1.41	5.468±1.37	5.463±1.44	4.986±1.22^a	5.288±1.6	4.835±1.06	5.152±1.33	Data unavailable	
Creatine, µmol/l	110.9±14.6	76.39±14.3	72.14±13.8	70.47±11.7	73.16±12.6	74±17.5	73.21±10.9	72.61±12.0	Data unavailable	
Gamma-GT, U/l	Data unavailable		12.47±10.4^a	16.54±21.9	14.89±12.1^b	21.18±37.3	17.83±22.2	16.6±19.3	14.24±21.3^a	19.97±52.4

All values in the table were weighted according to national population. For blood concentrations of glucose, uric acid and lipids, please refer to Tables 33, 34 and 35, respectively

^a: p<.05; ^b: p<.001 t-test, comparison between users and controls in the same survey.

Tables

Table 42: Laboratory measurement for steroid hormone users and controls from survey BGS98 only

		GPT <i>u/L</i>	HbA1c %	Fructosamine <i>μmol/l</i>	Lipase <i>U/l</i>	Lipo (A) <i>mg/l</i>	Helicob. Pylori <i>U/ml</i>	Antithrombin <i>g/l</i>	Fibrinogen <i>g/l</i>	Ig E <i>IU/l</i>	TSH <i>mU/l</i>
Contraceptive	Users	9.41±4.71	5.13±.41	239.9±23.5	93.8±46.8	167.3±228	43.26±93.3	.284±.045	2.910±.620	107.0±331	1.25±.96
	Controls	10.6±8.77	5.22±.42	233.6±22.6	87.2±41.3	219.2±307	46.70±94.6	.300±.043	2.847±.675	117.3±314	1.16±1.35
	p value*	.004	.000	.000	.012	.001	.539	.000	.110	.590	.223
HRT	Users	10.56±4.7	5.54±.54	236.5±23.2	100.9±42	278.7±385	84.3±128.4	.294±.045	3.055±.657	71.1±130	.96±.866
	Controls	12.86±7.8	5.77±.80	240.0±32.5	97.7±48.2	335.6±407	107.4±137.7	.307±.044	3.370±.768	84.0±209	1.06±1.23
	p value*	.000	.000	.036	.182	.020	.004	.000	.000	.251	.086

All values in the table were weighted according to national population

*: t-test, comparing between users and controls.

Tables

Table 43: Multivariate unconditional logistic regression for the use of contraceptives in the five National Health Survey from 1984 to 1999 in Germany

		T0		T1		T2		T3		BGS98	
		OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p	OR (95%CI)	p
Age*	18-24									9.81(5.99-16.1)	.000
	25-29	5.85(3.70-9.25)	.000	11.1(7.20-17.10)	.000	11.0(7.04-17.3)	.000	4.56(2.53-8.24)	.000	3.76(2.49-5.66)	.000
	30-34	3.19(2.03-5.00)	.000	6.32(4.15-9.63)	.000	5.02(3.30-7.64)	.000	4.00(2.29-6.98)	.000	3.05(2.11-4.40)	.000
	35-39	2.39(1.55-3.67)	.000	3.62(2.33-5.62)	.000	4.10(2.66-6.32)	.000	2.69(1.57-4.58)	.000	2.61(1.82-3.73)	.000
	>40	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
Residence	<i>Countryside</i>	0.73(0.42-1.25)	.251	1.30(0.81-2.10)	.282	0.95(0.57-1.57)	.837	1.17(0.74-1.85)	.504	1.12(0.75-1.69)	.573
	<i>Small city</i>	0.59(0.39-0.91)	.018	0.98(0.66-1.46)	.927	1.14(0.76-1.70)	.532	1.27(0.73-2.19)	.395	1.59(1.08-2.33)	.019
	<i>Middle city</i>	0.80(0.52-1.23)	.315	1.01(0.67-1.51)	.970	1.66(1.13-2.44)	.010	0.97(0.60-1.58)	.906	1.02(0.71-1.45)	.924
	<i>Large city</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
BMI	<i>Under-weighted</i>	1.76(1.11-2.8)	.017	1.91(1.22-3.00)	.005	1.22(0.79-1.87)	.373	1.5(0.94-2.39)	.088	1.25(0.85-1.85)	.26
	<i>Normal</i>	1.46(0.95-2.24)	.085	1.76(1.18-2.65)	.006	1.30(0.89-1.90)	.169	1.62(1.09-2.40)	.018	1.43(1.01-2.02)	.043
	<i>Over-weighted</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
Marriage	<i>Single</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>Married</i>	0.85(0.46-1.56)	.598	0.78(0.47-1.30)	.341	1.09(0.65-1.82)	.751	0.61(0.31-1.22)	.165	0.73(0.53-0.99)	.045
	<i>Divorced</i>	0.49(0.20-1.21)	.120	0.66(0.28-1.56)	.339	2.03(0.88-4.70)	.099	0.62(0.25-1.52)	.298	0.64(0.34-1.21)	.173
	<i>Widowed</i>	0.20(0.03-1.53)	.121	0.93(0.13-6.44)	.941	0.95(0.20-4.54)	.95	0.36(0.06-2.34)	.287	2.07(0.27-16.2)	.487
Education	<i>Primary (Haupt)</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>Middle (Real-)</i>	0.83(0.56-1.24)	.362	0.71(0.49-1.02)	.064	0.90(0.63-1.30)	.586	1.03(0.61-1.73)	.923	1.06(0.73-1.54)	.744
	<i>Higher (FH und Uni)</i>	0.50(0.28-0.88)	.016	0.68(0.41-1.12)	.128	0.68(0.42-1.09)	.105	1.79(0.84-3.83)	.132	1.15(0.75-1.77)	.522
	<i>Others</i>	0.18(0.03-1.15)	.07	2.15(0.73-6.32)	.163	1.30(0.47-3.60)	.609	0.76(0.13-4.42)	.757	0.64(0.32-1.31)	.222
Income	<i>Low</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>Middle</i>	1.18(0.75-1.85)	.474	1.45(0.95-2.22)	.085	1.13(0.71-1.81)	.595	Unavailable		1.48(1.02-2.14)	.041
	<i>High</i>	1.31(0.65-2.64)	.453	1.46(0.79-2.70)	.229	1.22(0.69-2.15)	.49	Unavailable		2.19(1.27-3.77)	.005
Smoking	<i>Non-smoker</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>Former smoker</i>	1.04(0.68-1.59)	.851	1.26(0.85-1.88)	.246	1.21(0.81-1.79)	.353	1.43(0.87-2.32)	.155	0.97(0.64-1.47)	.885
	<i>Current smoker</i>	1.43(0.98-2.08)	.062	1.47(1.05-2.05)	.023	1(0.71-1.40)	.987	0.93(0.63-1.37)	.704	1.17(0.87-1.57)	.313

Tables

Social class	<i>Lower</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>Middle</i>	1.06(0.67-1.68)	.810	0.77(0.49-1.22)	.264	1.09(0.65-1.82)	.743	1.07(0.59-1.94)	.823	1.45(0.97-2.16)	.072
	<i>Upper</i>	1.09(0.52-2.30)	.815	0.78(0.38-1.59)	.498	1.03(0.52-2.04)	.932	0.60(0.27-1.32)	.202	0.88(0.48-1.60)	.676
Number of pregnancies	<i>0</i>	0.94(0.47-1.86)	.850	1.46(0.79-2.71)	.228	2.16(1.1-4.24)	.024	0.44(0.18-1.08)	.072	Unavailable	
	<i>1</i>	1.27(0.69-2.36)	.444	1.44(0.83-2.48)	.193	2.22(1.21-4.07)	.010	1.56(0.87-2.77)	.134	Unavailable	
	<i>2</i>	1.78(0.98-3.25)	.059	1.21(0.72-2.05)	.467	2.48(1.37-4.46)	.003	1.77(1.03-3.02)	.037	Unavailable	
	<i>>=3</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)			
Main household earner	<i>No</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>Yes</i>	2.36(1.4-3.99)	.001	0.78(0.49-1.26)	.316	0.73(0.45-1.17)	.190	0.94(0.63-1.41)	.764	1.21(0.85-1.73)	.284
Sports	<i>0 hour/wk</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>0-1 hour/7wk</i>	1.35(0.88-2.08)	.175	1.01(0.66-1.54)	.959	1.12(0.74-1.70)	.591	1.09(0.73-1.64)	.676	1.53(1.07-2.18)	.021
	<i>1-2 hours/7wk</i>	1.20(0.79-1.83)	.386	1.04(0.71-1.52)	.859	1.00(0.68-1.46)	.988	1.16(0.72-1.86)	.536	0.97(0.66-1.45)	.897
	<i>>2 hours/wk</i>	1.10(0.65-1.86)	.709	0.98(0.64-1.50)	.910	0.90(0.56-1.43)	.649	0.81(0.39-1.66)	.558	1.21(0.82-1.77)	.336
Alcohol	<i>No (0 g/day)</i>	1(Reference)		1(Reference)		1(Reference)		1(Reference)		1(Reference)	
	<i>Mild(1-20 g/day)</i>	1.12(0.75-1.68)	.581	1.08(0.76-1.54)	.659	1.15(0.80-1.65)	.446	1.38(0.91-2.10)	.131	1.33(0.97-1.84)	.077
	<i>Heavy (>20 g/day)</i>	1.32(0.91-1.93)	.146	0.90(0.63-1.28)	.563	1.24(0.87-1.77)	.228	0.98(0.65-1.48)	.920	1.09(0.76-1.56)	.627
Occurrence of diseases											
	<i>Regular cycle</i>	-	-	11.91(3.38-42.0)	.000	2.33(0.99-5.51)	.054	2.92(0.40-21.2)	.288	7.95(3.75-16.9)	.000
	<i>Hypertension</i>	0.93(0.56-1.53)	.763	2.18(1.39-3.42)	.001	2.21(1.38-3.53)	.001	1.74(1.11-2.71)	.015	1.45(0.95-2.21)	.086
	<i>Hyperlipidemia</i>	1.91(1.33-2.76)	.001	1.65(1.18-2.31)	.003	1.96(1.38-2.77)	.000	1.13(0.75-1.69)	.555	1.45(1.08-1.95)	.014
	<i>Hyperuricemia</i>	0.44(0.13-1.44)	.175	0.29(0.08-1.05)	.060	0.34(0.12-0.99)	.049	0.52(0.14-1.90)	.320	1.64(0.46-5.82)	.441
	<i>Gastric, duodenal ulcer</i>	1.57(0.66-3.78)	.311	5.19(2.14-12.6)	.000	0.93(0.43-1.98)	.846	0.42(0.12-1.41)	.159	0.68(0.27-1.70)	.412

*: Users vs nonusers in the general women population (<50 years of age), **: All ORs were referred to no occurrence of this specific disease, and adjusted for age, resident place, BMI, marriage status, education, (household income), smoking status, social class, (number of pregnancies), sports and alcohol consumption.

Tables

Table 44: Multivariate unconditional logistic regression for the use of HRT in the five National Health Survey from 1984 to 1999 in Germany

		T0		T1		T2		T3		BGS98	
		OR (95%CI)	p								
Age*	<40	-	-	0.06(0.01-0.51)	.009	0.02(0.01-0.07)	.000	0.08(0.01-0.47)	.005	0.02(0.01-0.05)	.000
	40-44	0.05(0.01-0.23)	.000	0.19(0.05-0.73)	.015	0.08(0.04-0.18)	.000	0.45(0.14-1.44)	.177	0.07(0.04-0.13)	.000
	45-49	0.27(0.10-0.73)	.010	1.09(0.49-2.42)	.829	0.29(0.16-0.51)	.000	0.97(0.34-2.76)	.954	0.28(0.18-0.44)	.000
	50-54	0.30(0.09-0.98)	.046	1.23(0.55-2.78)	.612	1.04(0.67-1.62)	.859	1.68(0.74-3.85)	.218	0.88(0.58-1.33)	.550
	55-59	1(Reference)									
	60-64	0.74(0.27-2.06)	.570	0.65(0.26-1.65)	.368	0.32(0.17-0.58)	.000	0.64(0.23-1.80)	.398	0.59(0.38-0.91)	.019
	65-69	0.66(0.19-2.29)	.513	0.23(0.07-0.75)	.016	0.12(0.05-0.29)	.000	-	-	0.45(0.27-0.75)	.002
	70-74									0.11(0.05-0.24)	.000
	75-79									0.09(0.04-0.23)	.000
Residence	<i>Countryside</i>	1.12(0.31-3.99)	.867	0.83(0.35-1.99)	.680	0.42(0.23-0.78)	.006	0.76(0.33-1.73)	.508	0.83(0.54-1.28)	.399
	<i>Small city</i>	0.46(0.15-1.39)	.168	0.87(0.44-1.71)	.680	0.41(0.26-0.67)	.000	0.77(0.28-2.14)	.613	1.05(0.69-1.59)	.832
	<i>Middle city</i>	0.83(0.30-2.28)	.723	0.77(0.37-1.61)	.485	0.74(0.48-1.15)	.184	0.52(0.21-1.32)	.169	1.19(0.83-1.72)	.340
	<i>Large city</i>	1(Reference)									
BMI	<i>Under-weighted</i>	2.36(0.71-7.84)	.162	1.33(0.47-3.75)	.593	2.04(1.17-3.57)	.012	1.52(0.40-5.74)	.534	2.25(1.29-3.91)	.004
	<i>Normal</i>	1.75(0.74-4.13)	.202	2.2(1.22-3.97)	.008	1.42(0.96-2.09)	.076	1.78(0.88-3.59)	.107	1.63(1.19-2.24)	.002
	<i>Over-weighted</i>	1(Reference)									
Marriage	<i>Single</i>	-	-	0.14(0.02-1.05)	.056	0.63(0.23-1.68)	.351	0.88(0.12-6.37)	.9	0.79(0.36-1.73)	.552
	<i>Married</i>	0.66(0.13-3.41)	.617	0.42(0.15-1.13)	.086	2.49(1.12-5.52)	.025	2.27(0.58-8.89)	.24	0.83(0.48-1.44)	.507
	<i>Divorced</i>	2.36(0.30-18.7)	.418	0.90(0.31-2.67)	.854	0.64(0.23-1.76)	.384	1.30(0.25-6.89)	.756	1.20(0.65-2.24)	.560
	<i>Widowed</i>	1(Reference)									
Education	<i>Primary (Haupt)</i>	1(Reference)									
	<i>Middle (Real-)</i>	0.41(0.13-1.32)	.134	1.12(0.53-2.38)	.770	1.15(0.73-1.83)	.547	0.64(0.25-1.59)	.332	1.07(0.75-1.54)	.696
	<i>Higher (FH und Uni)</i>	0.85(0.08-8.68)	.890	0.91(0.24-3.38)	.883	1.01(0.49-2.07)	.972	1.32(0.38-4.63)	.666	1.07(0.66-1.76)	.775
	<i>Others</i>	1.88(0.21-16.7)	.570	2.72(0.68-10.9)	.158	0.49(0.12-2.05)	.328	-	-	1.26(0.61-2.61)	.533

Tables

			Low	1(Reference)		1(Reference)		1(Reference)		Unavailable		1(Reference)	
Income	<i>Middle</i>	3.69(1.10-12.3)	.034	0.67(0.33-1.35)	.260	0.77(0.45-1.30)	.321	Unavailable		Unavailable		1.61(1.07-2.42)	.023
		9.69(1.74-54.0)	.010	0.51(0.19-1.41)	.194	0.55(0.27-1.12)	.097	Unavailable		Unavailable		0.77(0.41-1.44)	.405
Smoking	<i>Non-smoker</i>	2.28(0.68-7.59)	.179	1.76(0.85-3.66)	.129	1.14(0.73-1.78)	.571	1.55(0.59-4.05)	.370	0.97(0.67-1.42)	.881		
	<i>Former smoker</i>	5.78(1.47-22.6)	.012	2.45(1.00-5.99)	.049	1.63(0.95-2.80)	.078	1.67(0.61-4.58)	.317	1.28(0.80-2.06)	.298		
	<i>Current smoker</i>	1(Reference)											
Social class	<i>Lower</i>	1(Reference)											
	<i>Middle</i>	0.64(0.21-1.92)	.424	2.03(0.98-4.21)	.057	1.75(1.04-2.94)	.036	0.83(0.36-1.89)	.652	1.83(1.20-2.79)	.005		
	<i>Upper</i>	1.09(0.18-6.61)	.922	1.19(0.31-4.53)	.801	2.99(1.36-6.53)	.006	0.40(0.08-1.91)	.252	2.42(1.26-4.65)	.008		
Number of pregnancies	0	3.08(0.70-13.6)	.138	0.65(0.24-1.79)	.406	1.37(0.76-2.48)	.298	1.82(0.49-6.82)	.374	Unavailable			
	1	7.01(2.04-24.1)	.002	0.76(0.36-1.61)	.474	0.88(0.53-1.45)	.606	0.64(0.22-1.87)	.416	Unavailable			
	2	1.75(0.55-5.54)	.344	1.11(0.56-2.17)	.768	0.79(0.49-1.25)	.304	1.98(0.85-4.61)	.114	Unavailable			
	>=3	1(Reference)		1(Reference)		1(Reference)		1(Reference)					
Main household earner	<i>No</i>	1(Reference)											
	<i>Yes</i>	0.61(0.11-3.47)	.574	0.73(0.29-1.82)	.498	1.77(0.92-3.40)	.088	0.85(0.37-1.96)	.709	0.93(0.6-1.44)	.751		
Sports	<i>0 hour/wk</i>	1(Reference)											
	<i>0-1 hour/7wk</i>	1.10(0.37-3.23)	.861	0.49(0.19-1.24)	.133	1.44(0.87-2.40)	.156	1.99(0.90-4.36)	.088	1.50(0.96-2.32)	.072		
	<i>1-2 hours/7wk</i>	1.00(0.36-2.78)	.999	0.72(0.35-1.46)	.359	1.68(1.07-2.63)	.023	1.56(0.65-3.74)	.314	1.61(1.10-2.36)	.014		
	<i>>2 hours/wk</i>	0.45(0.09-2.27)	.335	1.80(0.84-3.87)	.132	1.11(0.62-1.99)	.731	0.75(0.13-4.45)	.756	1.61(1.05-2.46)	.029		
Alcohol	<i>No (0 g/day)</i>	1(Reference)											
	<i>Mild(1-20 g/day)</i>	1.07(0.38-2.99)	.900	1.59(0.84-3.03)	.156	1.06(0.69-1.62)	.789	2.08(0.87-4.99)	.101	1.16(0.82-1.65)	.405		
	<i>Heavy (>20 g/day)</i>	1.35(0.54-3.34)	.521	1.71(0.88-3.33)	.113	1.01(0.66-1.54)	.976	2.08(0.86-4.99)	.103	1.37(0.95-2.00)	.095		
Occurrence of diseases	**												
	<i>Cerebral circulation disorders</i>	2.06(0.70-6.03)	.188	1.90(0.79-4.57)	.149	1.70(0.92-3.14)	.087	0.55(0.11-2.78)	.472	0.64(0.15-2.69)	.542		
	<i>Arthritis</i>	0.70(0.32-1.54)	.371	1.25(0.69-2.29)	.458	1.90(1.28-2.81)	.001	1.38(0.62-3.04)	.428	1.39(0.98-1.98)	.067		
	<i>Gastritis</i>	1.70(0.71-4.06)	.234	1.34(0.69-2.60)	.386	1.55(1.02-2.36)	.040	1.48(0.61-3.56)	.384	1.54(1.12-2.12)	.008		
	<i>Hypertension</i>	1.66(0.77-3.56)	.197	0.98(0.57-1.69)	.954	1.17(0.81-1.71)	.405	0.83(0.43-1.62)	.585	0.93(0.68-1.28)	.669		
	<i>Diabetes</i>	0.64(0.11-3.78)	.626	1.33(0.52-3.37)	.549	0.41(0.16-1.07)	.068	1.36(0.47-3.94)	.576	0.32(0.13-0.78)	.012		

*: users vs nonusers in the general women population (>=35 years of age); **: All ORs were referred to no occurrence of this specific disease, and adjusted for age, resident place, BMI, marriage status, education, (household income), smoking status, social class, (number of pregnancies), sports and alcohol consumption.

Tables

Table 45: Descriptive characteristics of hypertensive patients and controls for the case-control study of hypertension in association with contraceptive use in younger adult women (<45 years) in the five National Health Surveys from 1984 to 1999, Germany

	T0		T1		T2		T3		BGS98	
	Cases	Controls								
n	198	367	217	403	202	375	170	276	277	500
Mean age, years	37.7±5.3	37.5±5.2	36.0±5.9	35.9±5.8	36.6±5.8	36.4±5.8	35.7±5.2	35.7±5.0	36.0±6.4	35.8±6.4
BMI, kg/m²	27.0±5.5^a	23.7±3.4	27.4±6.5^a	23.9±3.9	27.5±6.1^a	24.3±4.3	27.7±5.7^a	24.6±4.0	27.2±5.5^a	24.7±4.4
Blood Na, mmol/l	140.0±4.6	140.4±3.1	140.5±1.8	140.7±2.0	140.8±2.1	140.9±2.5	140.4±2.3	140.0±2.4	-	-
Smoking status (%)	P=.399		P=.474		P=.357		P=.010		P=.826	
<i>Never</i>	49.2	44.4	45.6	40.9	43.6	37.9	59.4	48.6	41.9	42.8
<i>Former</i>	19.8	24.4	19.4	22.6	21.3	21.6	17.6	14.9	20.2	18.4
<i>Current</i>	31.0	31.2	35.0	36.5	35.1	40.5	22.9	36.6	37.8	38.8
Alcohol use (%)	P=.420		P=.169		P=.443		P=.302		P=.296	
<i>No</i>	37.8	38.8	46.5	39.2	41.3	38.4	30.6	33.0	49.6	44.1
<i>Mild</i>	21.4	25.4	23.5	28.9	26.4	31.5	28.2	33.0	31.8	33.7
<i>Heavy</i>	40.8	35.8	30.0	31.9	32.3	30.1	41.2	34.1	18.6	22.2
Social class (%)	P=.218		P=.044		P=.223		P=.406		P=.002	
<i>Lower</i>	25.0	20.0	22.9	14.9	16.9	14.5	14.1	10.9	17.0	16.4
<i>Middle</i>	56.6	56.4	58.9	63.7	60.2	56.0	68.2	67.4	67.4	57.0
<i>Upper</i>	18.4	23.6	18.2	21.4	22.9	29.5	17.6	21.7	15.5	26.6
Education (%)	P=.086		P=.393		P=.009		P=.228		P=.144	
<i>Primary</i>	68.0	60.0	61.8	56.6	61.4	46.9	21.2	17.1	27.5	25.4
<i>Middle</i>	17.3	26.0	25.3	28.0	22.3	31.7	62.4	60.7	49.1	43.4
<i>Higher</i>	12.2	12.6	9.7	13.2	13.4	18.7	15.3	21.8	21.1	27.6
<i>Others</i>	2.5	1.4	3.2	2.2	3.0	2.7	1.2	.4	2.3	3.7
Hyperlipidemia (%)	P=.001		P=.000		P=.005		P=.027		P=.002	
	77.5	63.3	78.9	63.5	79.2	68.0	75.7	65.8	75.7	64.6
Contraceptive use, n (%)	P=.789		P=.030		P=.080		P=.120		P=.023	
	37(18.7)	72(19.6)	68(31.3)	94(23.3)	46(22.8)	63(16.8)	83(48.8)	114(41.3)	91(32.9)	126(25.2)

^a: p<.001, t-test, comparison between cases and controls in the same survey.

Tables

Table 46: Odds ratio and 95% confidence intervals of hypertension in association with contraceptive use in the five National Health Surveys from 1984 to 1999, Germany

	T0		T1		T2		T012**		T3		BGS98	
	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Unadjusted												
OC nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
OC users	0.99	0.62-1.58	1.59	1.08-2.34	1.57	1.01-2.46	1.38	1.08-1.76	1.37	0.93-2.01	1.56	1.09-2.24
Low estrogen dose ¹	0.86	0.46-1.68	1.53	0.98-2.41	1.84	1.13-3.00	1.44	1.07-1.92	1.29	0.77-2.15	1.58	1.09-2.30
High estrogen dose ²	1.11	0.61-2.03	1.70	0.94-3.09	0.82	0.31-2.15	1.27	0.87-1.87	1.43	0.90-2.25	1.44	0.60-3.44
Monophasic OCs	1.13	0.67-1.94	1.26	0.78-2.05	1.52	0.90-2.56	1.28	0.96-1.73	1.46	0.96-2.23	1.54	1.01-2.35
Multi-phasic OCs	0.74	0.33-1.65	2.17	1.27-3.72	1.70	0.83-3.48	1.55	1.07-2.55	1.13	0.61-2.08	1.60	0.93-2.75
Adjusted*												
OC nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
OC users	1.03	0.62-1.70	1.90	1.26-2.88	1.75	1.09-2.80	1.58	1.22-2.05	1.73	1.14-2.63	1.68	1.16-2.43
Low estrogen dose ¹	1.04	0.52-2.08	1.83	1.13-2.96	2.14	1.28-3.59	1.72	1.26-2.33	1.78	1.03-3.09	1.70	1.16-2.51
High estrogen dose ²	1.01	0.52-1.96	2.06	1.09-3.88	0.77	0.28-2.13	1.36	0.91-2.04	1.70	1.04-2.77	1.50	0.61-3.70
Monophasic OC	1.12	0.62-2.00	1.46	0.87-2.44	1.71	0.98-3.00	1.44	1.06-1.97	1.82	1.16-2.88	1.70	1.10-2.62
Multi-phasic OC	0.85	0.36-2.00	2.72	1.53-4.84	1.82	0.87-3.83	1.85	1.25-2.73	1.49	0.77-2.87	1.64	0.94-2.88

¹: A low dose was defined as less than 50 µg of ethinyl estradiol or less than 75µg of mestranol. ²: A high dose was defined as 50 µg or more of ethinyl estradiol or 75µg or more of mestranol

*: Adjusted for residence, body mass index, education, household income, smoking status, social class, sports activities, alcohol use, hyperlipidemia and blood concentration of sodium.

**: The merging of surveys T0, T1 and T2.

Tables

Table 47: Descriptive characteristics of hyperlipidemia patients and controls for the case-control study of hyperlipidemia in association with contraceptive use in younger adults women (<45 years) in the five National Health Surveys from 1984 to 1999, Germany

	T0		T1		T2		T3		BGS98	
	Cases	Controls								
n	288	392	294	399	335	455	140	199	353	479
Mean age, years	36.1±5.8	36.0±5.9	34.8±6.3	34.7±6.1	35.4±5.7	35.5±5.8	35.8±5.5	35.6±5.4	34.0±6.9	34.0±7.0
BMI, kg/m²	25.4±4.7^a	23.7±3.9	25.7±5.0^a	23.9±4.3	26.0±5.6^a	24.1±3.8	26.7±5.1^a	25.0±4.5	25.0±4.9^a	24.4±4.5
Smoking status (%)	P=.004		P=.752		P=.009		P=.266		P=.473	
<i>Never</i>	36.5	48.2	39.8	42.4	32.5	43.1	50.0	57.3	40.3	44.5
<i>Former</i>	22.2	21.5	19.7	19.8	22.4	20.2	13.6	14.6	18.4	16.4
<i>Current</i>	41.3	30.3	40.5	37.8	45.1	36.7	36.4	28.1	41.2	39.1
Alcohol use (%)	P=.116		P=.330		P=.187		P=.065		P=.124	
<i>No</i>	42.5	35.8	44.2	39.9	44.9	39.1	28.6	36.7	50.7	44.0
<i>Mild</i>	23.0	29.2	28.9	28.1	25.4	30.5	31.4	35.2	31.2	33.3
<i>Heavy</i>	34.5	35.0	26.9	31.9	29.6	30.3	40.0	28.1	18.1	22.6
Social class (%)	P=.430		P=.393		P=.002		P=.172		P=.238	
<i>Lower</i>	22.2	19.1	20.1	16.7	19.5	10.6	15.7	11.1	19.2	14.7
<i>Middle</i>	58.0	57.6	63.5	64.1	56.2	61.2	70.0	67.8	61.0	64.4
<i>Upper</i>	19.8	23.3	16.4	19.2	24.3	28.2	14.3	21.1	19.8	20.9
Education (%)	P=.506		P=.425		P=.001		P=.097		P=.590	
<i>Primary</i>	59.7	59.5	57.5	55.4	55.8	44.8	25.2	16.6	25.7	22.6
<i>Middle</i>	26.4	23.6	28.2	26.8	26.9	31.6	56.8	62.3	42.8	47.1
<i>Higher</i>	11.8	15.4	11.6	15.8	14.3	22.4	15.8	20.6	27.2	26.7
<i>Others</i>	2.1	1.5	2.7	2.0	3.0	1.1	2.2	.5	4.3	3.6
Hypertension (%)	P=.000		P=.000		P=.001		P=.106		P=.121	
	27.8	14.0	30.0	15.0	24.2	14.5	36.4	28.1	21.7	17.4
Contraceptive use, <i>n (%)</i>	P=.938		P=.036		P=.021		P=.917		P=.965	
	58(20.1)	78(19.9)	91(31.0)	95(23.8)	83(24.8)	82(18.0)	59(42.1)	85(42.7)	114(32.3)	154(32.6)

^a: p<.001, t-test, comparison between case and controls in the same survey.

Tables

**Table 48: Odds ratio and 95% confidence intervals of hyperlipidemia in association with contraceptive use
in the five National Health Surveys from 1984 to 1999, Germany**

	T0		T1		T2		T012**		T3		BGS98	
	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Unadjusted												
OC nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
OC users	1.06	0.76-1.58	1.47	1.04-2.08	1.54	1.08-2.19	1.36	1.11-1.68	0.95	0.61-1.48	1.06	0.76-1.46
Low estrogen dose ¹	1.40	0.83-2.36	1.23	0.82-1.85	1.64	1.12-2.42	1.41	1.11-1.80	0.82	0.44-1.53	1.01	0.72-1.43
High estrogen dose ²	0.80	0.46-1.38	2.08	1.21-3.58	1.22	0.61-2.44	1.29	0.92-1.79	1.04	0.63-1.73	1.34	0.65-2.75
Monophasic OCs	1.52	0.92-2.53	1.31	0.85-2.03	1.51	1.00-2.30	1.43	1.10-1.85	1.00	0.62-1.63	0.86	0.58-1.28
Multi-phasic OCs	0.68	0.38-1.21	1.69	1.05-2.72	1.60	0.92-2.78	1.28	0.94-1.72	0.81	0.40-1.67	1.44	0.91-2.29
Adjusted*												
OC nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
OC users	1.09	0.72-1.64	1.57	1.10-2.25	1.58	1.10-2.28	1.43	1.15-1.77	1.02	0.64-1.62	1.10	0.79-1.52
Low estrogen dose ¹	1.35	0.78-2.33	1.35	0.89-2.06	1.69	1.13-2.52	1.46	1.14-1.89	0.85	0.45-1.63	1.06	0.75-1.50
High estrogen dose ²	0.86	0.49-1.52	2.16	1.23-3.79	1.22	0.59-2.50	1.37	0.97-1.92	1.13	0.67-1.92	1.34	0.65-2.78
Monophasic OC	1.46	0.86-2.47	1.45	0.92-2.29	1.55	1.01-2.39	1.48	1.13-1.93	1.08	0.65-1.78	0.91	0.61-1.35
Multi-phasic OC	0.74	0.40-1.35	1.78	1.08-2.87	1.62	0.92-2.87	1.36	1.00-1.86	0.87	0.41-1.83	1.46	0.91-2.33

¹: A low dose was defined as less than 50 µg of ethinyl estradiol or less than 75µg of mestranol. ²: A high dose was defined as 50 µg or more of ethinyl estradiol or 75µg or more of mestranol

*: Adjusted for residence, body mass index, education, household income, smoking status, social class, sports activities, alcohol use.

**: The merging of surveys T0, T1 and T2.

Tables

Table 49: Descriptive characteristics of diabetic patients and controls for the case-control study of diabetes in association with HRT use in elderly women (≥ 45 years) in the five National Health Surveys from 1984 to 1999, Germany

	T0		T1		T2		T3		BGS98	
	Cases	Controls								
n	102	380	142	528	119	412	72	205	196	521
Mean age, years	58.6 \pm 5.8	58.8 \pm 5.8	59.1 \pm 6.8	59.1 \pm 5.9	58.7 \pm 6.3	58.9 \pm 6.3	58.7 \pm 7.3	58.6 \pm 7.4	65.6 \pm 8.3	65.4 \pm 8.2
BMI, kg/m²	29.6\pm5.0^a	27.2 \pm 4.6	29.4\pm5.5^a	27.2 \pm 4.5	30.5\pm6.2^a	27.9 \pm 5.2	31.4\pm6.0^a	28.8 \pm 6.0	31.2\pm5.6^a	27.9 \pm 4.7
Smoking status (%)	P=.217		P=.754		P=.765		P=.548		P=.032	
<i>Never</i>	76.2	67.4	70.4	68.9	70.6	68.7	82.1	76.2	82.3	72.6
<i>Former</i>	11.9	15.0	11.3	13.6	12.6	15.3	7.7	11.2	8.8	12.6
<i>Current</i>	11.9	17.6	18.3	17.4	16.8	16.0	10.3	12.6	8.8	14.8
Alcohol use (%)	P=.700		P=.645		P=.132		P=.079		P=.001	
<i>No</i>	52.0	47.6	55.6	51.2	52.9	45.6	56.4	41.7	66.3	50.4
<i>Mild</i>	21.6	22.1	23.2	25.2	29.4	27.9	23.1	29.6	19.3	26.9
<i>Heavy</i>	26.5	30.3	21.1	23.5	17.6	26.5	20.5	28.7	14.4	22.7
Social class (%)	P=.003		P=.046		P=.098		P=.287		P=.004	
<i>Lower</i>	59.8	40.8	42.6	42.7	45.4	37.2	50.0	42.8	51.4	37.6
<i>Middle</i>	33.3	49.1	51.8	44.6	47.1	48.9	46.2	48.6	40.3	48.7
<i>Upper</i>	6.9	10.1	5.7	12.7	7.6	13.9	3.8	8.6	8.3	13.8
Education (%)	P=.096		P=.279		P=.259		P=.657		P=.066	
<i>Primary</i>	87.3	75.8	83.1	76.1	82.4	75.0	76.9	70.6	75.7	65.3
<i>Middle</i>	6.9	14.2	12.7	15.9	8.4	15.3	16.7	18.6	12.7	20.6
<i>Higher</i>	3.9	6.1	2.8	6.1	5.0	4.6	5.1	8.6	7.7	9.1
<i>Others</i>	2.0	3.9	1.4	1.9	4.2	5.1	1.3	2.3	3.9	5.0
Hyperlipidemia(%)	P=.637		P=.230		P=.091		P=.044		P=.992	
	94.1	95.3	95.8	93.0	98.3	94.7	96.2	88.3	93.9	93.9
Hypertension (%)	P=.006		P=.008		P=.022		P=.002		P=.018	
	71.6	56.6	73.2	61.2	73.9	62.6	88.5	70.4	79.5	70.7
HRT use, n (%)	P=.212		P=.726		P=.108		P=.197		P=.000	
	1(1.0)	15(3.9)	6(4.2)	19(3.6)	8(6.7)	49(11.9)	7(9.7)	11(5.4)	12(6.1)	95(18.2)

^a: p<.001t-test, comparison between case and controls in the same survey.

Tables

Table 50: Odds ratio and 95% confidence intervals of diabetes in association with HRT use in elderly women(>45 years) in the five National Health Surveys from 1984 to 1999 in Germany

	T0		T1		T2		T012**		T3		BGS98	
	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Unadjusted												
HRT nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
HRT users	0.29	0.04-2.24	1.32	0.51-3.41	0.52	0.23-1.18	0.68	0.38-1.22	1.76	0.67-4.64	0.19	0.08-0.44
Estrogen only	0.31	0.04-2.44	0.53	0.13-2.16	0.97	0.38-2.50	0.80	0.37-1.73	1.51	0.37-6.12	0.34	0.12-1.00
Estrogen+progestin	-	-	0.55	0.08-3.59	0.13	0.01-1.14	0.30	0.09-0.99	2.01	0.55-7.33	0.05	0.01-0.39
Conjugated estrogen ¹	-	-	0.42	0.05-3.32	0.34	0.08-1.50	0.31	0.09-1.01	-	-	0.31	0.07-1.37
Normal estrogen ¹	0.63	0.07-5.26	2.35	0.75-7.29	0.65	0.24-1.75	1.01	0.51-2.00	2.64	0.92-7.54	0.12	0.04-0.4
Adjusted*												
HRT nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
HRT users	0.30	0.04-2.44	1.47	0.55-4.00	0.64	0.27-1.51	0.81	0.45-1.48	2.86	0.96-8.50	0.32	0.13-0.78
Estrogen only	0.33	0.04-2.70	0.50	0.12-2.11	0.79	0.30-2.12	0.68	0.31-1.49	2.13	0.46-9.76	0.64	0.21-2.00
Estrogen+progestin	-	-	0.58	0.08-3.98	0.13	0.01-1.22	0.31	0.09-1.03	3.87	0.85-17.72	0.08	0.01-0.63
Conjugated estrogen ¹	-	-	0.59	0.07-4.87	0.39	0.09-1.73	0.38	0.11-1.24	-	-	0.58	0.12-2.77
Normal estrogen ¹	0.70	0.08-6.26	2.19	0.67-7.18	0.87	0.32-2.41	1.12	0.60-2.40	5.14	1.51-17.55	0.21	0.06-0.69

¹: with or without progestins;

*: Adjusted for residence place, body mass index, education, household income, smoking status, social class, sports activities, alcohol use, hypertension and hyperlipidemia.

**: The merging of surveys T0, T1 and T2.

Tables

Table 51: Descriptive characteristics of arthritis patients and controls for the case-control study of arthritis in association with HRT use in elderly women (≥ 45 years) in the five National Health Survey from 1984 to 1999, Germany

	T0		T1		T2		T3		BGS98	
	Cases	Controls								
n	471	469	501	501	473	473	137	197	833	712
Mean age, years	56.8±6.9	56.7±7.0	58.4±5.1	58.5±5.1	57.2±6.6	57.1±6.7	57.8±6.3	58.1±6.4	61.1±8.7	61.3±8.6
BMI, kg/m²	27.9±4.9^a	26.7±4.6	27.9±5.0^b	27.1±5.3	28.4±5.6^b	27.6±4.9	29.1±5.3^b	27.9±5.4	28.9±5.2^a	27.8±5.2
Smoking status (%)	P=.584		P=.409		P=.499		P=.916		P=.375	
<i>Never</i>	71.1	69.2	67.9	67.9	68.7	65.8	78.1	78.7	70.9	71.3
<i>Former</i>	11.7	13.9	15.4	13.0	16.1	16.3	10.9	9.6	14.6	12.5
<i>Current</i>	17.2	16.9	16.8	19.2	15.2	18.0	10.9	11.7	14.5	16.2
Alcohol use (%)	P=.041		P=.024		P=.712		P=.657		P=.373	
<i>No</i>	45.2	52.1	55.4	49.3	42.5	45.1	41.6	43.7	52.9	50.7
<i>Mild</i>	27.2	20.7	26.4	25.5	27.9	26.9	33.6	24.4	25.0	28.2
<i>Heavy</i>	27.6	27.1	18.2	25.1	29.6	28.0	24.8	32.0	22.1	21.1
Social class (%)	P=.394		P=.832		P=.741		P=.453		P=.137	
<i>Lower</i>	42.5	44.6	40.0	41.8	37.2	34.7	45.2	46.2	35.5	36.3
<i>Middle</i>	47.0	42.9	48.6	46.8	48.0	50.0	50.4	46.2	51.3	47.3
<i>Upper</i>	10.5	12.4	11.4	11.4	14.9	15.3	4.4	7.6	13.2	16.4
Education (%)	P=.910		P=.995		P=.811		P=.875		P=.091	
<i>Primary</i>	77.5	76.5	77.0	76.4	74.0	75.0	79.6	78.5	65.8	60.9
<i>Middle</i>	14.2	13.9	15.0	15.2	15.9	15.9	10.2	11.3	21.8	23.5
<i>Higher</i>	5.9	7.1	5.6	5.8	7.2	5.7	5.8	7.2	8.1	11.5
<i>Others</i>	2.3	2.6	2.4	2.6	3.0	3.4	4.4	3.1	4.4	4.1
HRT use, n(%)	P=.606		P=1.00		P=.021		P=.677		P=.077	
	17(3.6)	20(4.3)	27(5.4)	27(5.4)	81(17.1)	56(11.8)	14(10.2)	23(11.7)	196(23.5)	141(19.8)

^a: p<.001, ^b: p<0.05, t-test, comparison between case and controls in the same survey.

Tables

Table 52: Odds ratio and 95% confidence intervals of arthritis in association with HRT use in elderly women(>45 years) in the five National Health Surveys from 1984 to 1999 in Germany

	T0		T1		T2		T012**		T3		BGS98	
	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI	OR	95% CI
Unadjusted												
HRT nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
HRT users	0.85	0.44-1.64	1.00	0.58-1.72	1.54	1.06-2.23	1.23	0.94-1.62	0.87	0.43-1.75	1.23	0.96-1.58
Estrogen only	0.88	0.43-1.78	1.20	0.60-2.40	1.44	0.84-2.45	1.19	0.83-1.71	0.95	0.38-2.40	1.36	0.94-1.96
Estrogen+progestin	0.66	0.11-3.99	0.75	0.31-1.79	1.48	0.91-2.41	1.19	0.80-1.79	0.78	0.28-2.16	1.16	0.85-1.57
Conjugated estrogen ¹	0.38	0.14-1.08	1.00	0.43-2.32	1.14	0.65-2.03	0.89	0.58-1.35	2.00	0.62-6.44	1.67	1.06-2.63
Normal estrogen ¹	1.71	0.67-4.38	1.00	0.49-2.02	1.70	1.07-2.72	1.46	1.03-2.09	0.55	0.22-1.37	1.11	0.84-1.46
Adjusted*												
HRT nonusers	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference	1	Reference
HRT users	0.93	0.47-1.82	1.11	0.64-1.94	1.61	1.10-2.36	1.30	0.98-1.71	0.93	0.45-1.91	1.33	1.03-1.72
Estrogen only	0.93	0.46-1.91	1.33	0.66-2.70	1.49	0.87-2.56	1.24	0.86-1.78	1.00	0.39-2.56	1.42	0.98-2.07
Estrogen+progestin	0.90	0.15-5.60	0.83	0.34-2.01	1.56	0.95-2.58	1.28	0.85-1.93	0.85	0.30-2.42	1.27	0.92-1.74
Conjugated estrogen ¹	0.39	0.14-1.11	1.10	0.47-2.60	1.17	0.65-2.09	0.91	0.60-1.39	2.25	0.68-7.42	1.75	1.10-2.78
Normal estrogen ¹	2.06	0.79-5.42	1.11	0.54-2.27	1.81	1.12-2.93	1.57	1.09-2.25	0.58	0.23-1.46	1.20	0.90-1.61

¹: with or without progestins;

*: Adjusted for residence place, body mass index, education, smoking status, social class, alcohol use.

**: The merging of surveys T0, T1 and T2.

Tables

Table 53: Comparison of HRT users with controls for some continuous parameters concerning lipids, coagulation, glycemic status and blood pressure from survey BGS98 by using three different methods

	Method A (Mean±SD)			Method B (Mean±SD)			Method C (Mean±SE)		
	HRT Users (N=427)	Controls (N=854)	P ^A	HRT Users (N=317)	Controls (N=315)	P ^B	HRT Users (N=427)	Controls (N=854)	P ^C
Blood lipids	Total cholesterol mmol/l	6.342±1.10	6.579±1.21	.001	6.328±1.13	6.645±1.29	.001	6.319±.058	6.595±.041
	Triglycerides mmol/l	1.389±.749	1.588±.965	.000	1.398±.770	1.642±1.033	.001	1.449±.045	1.575±.033
	HDL-C mmol/l	1.754±.494	1.638±.470	.000	1.771±.504	1.648±.463	.002	1.716±.023	1.669±.016
	LDL-C mmol/l	3.957±1.01	4.219±1.06	.000	3.922±1.03	4.251±1.14	.000	3.944±.051	4.210±.037
	Lipo (A) mg/l	278.7±385	335.6±407	.020	265.4±357	350.2±421	.008	259.0±19.3	323.3±13.4
Coagula -tion	Fibrinogen g/l	3.055±.657	3.370±.768	.000	3.045±.668	3.313±.707	.000	3.103±.035	3.349±.025
	Antithrombin III g/l	.294±.045	.307±.044	.000	.294±.044	.306±.043	.001	.296±.002	.309±.002
Glycemic status	Fasting glucose mmol/l	5.296±.74 ^a	5.752±1.78	.000	5.269±.718	5.614±1.524	.000	5.391±.073	5.725±.052
	Fructosamine μmol/l	236.5±23.2	240.0±32.5	.036	235.6±23.0	239.5±33.4	.100	236.4±1.52	240.6±1.09
	HbA1c %	5.54±.54	5.77±.80	.000	5.52±.51	5.73±.77	.000	5.59±.034	5.76±.025
Blood pressure	SBP mm Hg	140.9±20.5	143.8±22.0	.023	140.7±21.4	144.6±22.6	.024	142.1±.97	143.3±.69
	DBP mm Hg	84.9±10.3	85.7±11.3	.242	84.6±10.8	86.5±11.0	.029	85.6±.52	85.4±.37

^A: t-test, controls were matched on age only; ^B: t-test, controls were matched on age and social class, HRT users and control were from West Germany only; ^C: univariate covariance analysis, adjusting for age, BMI, social class and region (West or East Germany).